Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Participants

Novartis AG Investor Relations

Q4 and FY 2019 Results Investor Presentation January 29, 2020 Disclaimer

This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as “potential,” “expected,” “will,” “planned,” “pipeline,” “outlook,” “may,” “could,” “would,” “anticipate,” “seek,” or similar expressions, or by express or implied discussions regarding potential new products, potential new indications for existing products, potential product launches, or regarding potential future revenues from any such products; or regarding the development or adoption of potentially transformational technologies, treatment modalities and business models; or regarding potential future or pending transactions, including the potential outcome, or financial or other impact on Novartis, of the proposed divestiture of certain portions of our Sandoz Division business in the US; or regarding the potential impact of share buybacks; or regarding potential future sales or earnings of the Group or any of its divisions or potential shareholder returns; or by discussions of strategy, plans, expectations or intentions. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. You should not place undue reliance on these statements. In particular, our expectations could be affected by, among other things: global trends toward healthcare cost containment, including ongoing government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; uncertainties regarding potential significant breaches of data security or data privacy, or disruptions of our information technology systems; regulatory actions or delays or government regulation generally, including potential regulatory actions or delays with respect to the proposed transactions or the development of the products described in this presentation; the potential that the proposed divestiture of certain portions of our Sandoz Division business in the US or the planned acquisition of the Japanese operations and associated assets of Aspen Global Incorporated, may not be completed in the expected time frame, or at all; the potential that the strategic benefits, synergies or opportunities expected from the acquisition of The Medicines Company, the proposed divestiture of certain portions of our Sandoz Division business in the US, or the planned acquisition of the Japanese operations and associated assets of Aspen Global Incorporated, and other transactions described, may not be realized or may be more difficult or take longer to realize than expected; the successful integration of The Medicines Company into the Novartis Group and the timing of such integration; potential adverse reactions to the transaction by customers, suppliers or strategic partners; dependence on key personnel of The Medicines Company; dependence on third parties to fulfill manufacturing and supply obligations; the uncertainties involved in predicting shareholder returns; the uncertainties in the research and development of new healthcare products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products that commenced in prior years and is expected to continue this year; safety, quality, data integrity, or manufacturing issues; uncertainties involved in the development or adoption of potentially transformational technologies and business models; uncertainties regarding actual or potential legal proceedings, including, among others, product liability litigation, disputes and litigation with business partners or business collaborators, government investigations generally, litigation and investigations regarding sales and marketing practices, and intellectual property disputes; our performance on environmental, social and governance measures; general political, economic and trade conditions, including uncertainties regarding the effects of ongoing instability in various parts of the world; uncertainties regarding future global exchange rates; uncertainties regarding future demand for our products; and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this presentation as of this date and does not undertake any obligation to update any forward- looking statements as a result of new information, future events or otherwise.

2 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Participants

Vas Narasimhan John Tsai Chief Executive Officer Head of Global Drug Development and CMO

Harry Kirsch Richard Saynor Chief Financial Officer CEO, Sandoz

Marie-France Tschudin Shannon Thyme Klinger President, Novartis Pharmaceuticals Group General Counsel

Susanne Schaffert President, Novartis Oncology

3 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation 4 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation In 2019, we kept executing on our strategy Focus Novartis as a leading medicines company powered by advanced therapy platforms and data science

Our focus Our priorities

Focus our company Strengthen our core Deliver transformative Embrace operational Go big on data and and capital innovation excellence every day digital

Accelerate Unleash the power of Build trust with society key geographies our people

5 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation We have focused Novartis as a medicines company

Medicinal chemistry Diversified Portfolio Focused medicines company powered by and industrials healthcare group transformation advanced therapy platforms and data science 1920 - 1996 1996 - 2009 2009 - 2017 2018 - 2019

Acquired Divested OTC1 Acquired Acquired Spun off Acquired Acquired

USD 3.9bn USD 13bn USD 8.7bn USD 2.1bn USD 28bn2 USD 3.4bn3 USD 9.7bn

1. OTC – Consumer Healthcare 2. Alcon market capitalization on close of 1st day of trading 3. USD 3.4bn upfront + potential milestone payments of up to USD 1.9bn

6 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Transformative innovation Leading pipeline with strong replacement power

Scale Value Innovation # of projects1 Estimated 2024 sales from products launched between 2019-242 Advanced platform therapies 114 PHASE 1 / 2 #1 Replacement power 16 in clinical development

Company A Pipeline potentially Company B first-in-class / PHASE 3 37 Company C ~90% first-in-indication Company D Company E Company F Target areas of high 13 REGISTRATION Company G ~80% unmet need Company H Company I

1. Including Global Health, excluding Sandoz. 2. Innovative medicine product sales excl. Vaccines and LCM products (e.g. new formulations, combinations with off patent molecules); compound-based analysis (Phase 2 and 3) with additional indications allocated to 1st launch. Inclisiran included. Source: Novartis peer group analysis based on data from Evaluate Pharma (download from November 27, 2019)

7 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Transformative innovation 2019 was a breakthrough year for innovation

5 NME approvals of potential blockbusters 30+ major submissions 30+ clinical data readouts

aSPMS Select examples Select examples . Entresto® (JP) . Zolgensma® SMA . Cosentyx® nr-AxSpA (US/EU) . Cosentyx® . Ofatumumab (US) . Ofatumumab Breast cancer . Adakveo® (US/EU) . Entresto® . Beovu® (US/EU/JP) . Fevipiprant Wet AMD . INC280 (US) . Kisqali® . QVM149 / QMF149 (EU/JP) . INC280 Sickle cell disease . Inclisiran (US)1 . Inclisiran1

aSPMS – Active secondary progressive multiple sclerosis SMA – Spinal muscular atrophy AMD – age-related macular degeneration 1. Readout / submission by The Medicines Company

8 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Transformative innovation 2020 catalysts maintaining long-term momentum

Potential catalysts Select examples Major approvals1 Ofatumumab (OMB157) Capmatinib (INC280) Cosentyx® Relapsing MS NSCLC nr-axSpA QVM / QMF 149 Entresto® Inclisiran (KJX839) Asthma HFpEF (US) Hyperlipidemia (US) Major submissions2 Inclisiran (KJX839) AVXS-101 IT4 Alpelisib (BYL719) Hyperlipidemia (EU) SMA PROS 177Lu-PSMA-617 Spartalizumab (PDR001) combo Entresto® mCRPC Metastatic melanoma HFpEF (US) Major readouts3 177Lu-PSMA-617 Beovu® Entresto® (Phase 3) mCRPC DME Post-acute MI (IA5) Asciminib (ABL001) Kisqali® Jakavi® Chronic Myeloid Leukemia Breast cancer (MONALEESA-2 OS) Chronic GvHD Phase 3 starts TQJ230 LNP023 MBG453 CVRR PNH MDS Tropifexor (LJN452) Alpelisib (BYL719) Beovu® NASH Multiple indications6 PDR

1. First approval in any market. 2. First submission in any market 3. Readouts enabling submission, label change or pivotal trial initiation 4. FDA placed a partial clinical hold based on findings in a small preclinical animal study 5. Planned interim analysis expected Q1 2020 (full readout 2021) 6. HER2+ aBC, TNBC, ovarian cancer, head and neck cancer, PROS

9 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Transformative innovation Innovation driving growth in China

Number of NDA approvals1 . Growth driven by regulatory approvals from innovative pipeline, market access and optimizing resources 50+ . 13 NME approvals over the past 5 years, and 22 NRDL listings since 2017 x2 . Average # of NDAs expected to double in the next 5 years . 5 average NDA approvals / year 2015-2019 25 . 10 average NDA approvals expected / year 2020-2024 . 50+ NDA approvals planned over the next 5 years 2015-2019 2020-2024 Actual Expected . Goal to deliver >90% of 2024+ China submissions simultaneously with global submission

1. NDA approvals of new compounds and new indications

10 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Operational excellence Delivered strong performance in 2019

Continuing operations1, FY 2019, TSR as of YE 2019 47.4 bn +9% 33.5% +1.8% pts NET SALES (USD) vs. 2018 (cc2) IM CORE MARGIN2(%) vs. 2018 (cc2) 14.1 bn +17% 5.28 +17% CORE OPERATING INCOME2 (USD) vs. 2018 (cc2) CORE EPS2 (USD) vs. 2018 (cc2) 12.9 bn +15% 22.3% Top tier FREE CASH FLOW2 (USD) vs. 2018 (USD) 1-YEAR TSR3 (%) RANKING 3

1. Continuing operations as defined on page 45 of the Condensed Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz (including the US generic oral solids and dermatology portfolio), as well as the continuing corporate functions. 2. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 58 of the Condensed Financial Report. 3. TSR in USD from Jan 1st 2019, using 1 day average price at start and 3 month average price at end; ranking when compared to the global HC peer group as defined in the Novartis 2019 Annual Report

11 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Operational excellence Strong operational performance from growth drivers

Selected growth driver sales Growth drivers and recent launches Sales Growth vs. PY Growth vs. PY as % of Innovative Medicines sales USD Million USD Million cc 35% 3,551 714 28% Adakveo® 1,726 698 71% Luxturna® Mayzent® 361 361 nm Beovu® Lutathera® 441 274 160% 27% Aimovig® Piqray® 480 245 111% Xiidra® 1,416 242 23% Kymriah® 20% 278 202 nm Zolgensma® Lutathera® 192 192 nm Kisqali® 14% 1,338 183 20% Jakavi®

® 1,114 137 20% Ilaris Xolair® 1,173 134 19% Tafinlar®+Mekinist® 671 117 25% Promacta® Entresto® 116 116 nm 2016 2017 2018 2019 Cosentyx® nm – not meaningful

12 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Operational excellence Focused on launch excellence for 15 ongoing and upcoming major launches

Inclisiran (KJX839) Hyperlipidemia

Mayzent® Entresto® aSPMS HFpEF

Zolgensma® IV Ofatumumab (OMB157) AVXS-101 IT SMA Relapsing MS SMA

Piqray® Capmatinib (INC280) Alpelisib (BYL719) Breast Cancer NSCLC PROS

Beovu® Cosentyx® 177Lu-PSMA-617 Wet AMD nr-axSpA mCRPC

Adakveo® QVM / QMF 149 PDR001 combo Sickle cell disease Asthma Metastatic melanoma 2019 2020 2021

Ongoing Upcoming

13 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Operational excellence Zolgensma® strong launch (June) with FY 2019 sales of USD 361m

Broad access, strong patient demand Next steps

Q3 end (~) YE (~) Intrathecal formulation on partial clinical Patients treated commercially 100 200 hold – regulatory discussions ongoing

Commercial lives covered 90% 97% CHMP opinion anticipated Q1 2020 Medicaid lives covered 30% >50% Approval anticipated in H1 2020 Newborns screened1 30% 39% Decisions anticipated late 2020 or early Others Approval rate for on-label patients >99% 2021 in Switzerland, Canada, Australia

Global Managed Access Program initiated

1. Expected to reach 70% by end of 2020

14 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Operational excellence Committed to driving consistent margin expansion

Innovative Medicines Core margin (% rounded)

Mid to high + Sales momentum of key growth drivers and Mid 30s operational excellence on upcoming launches 34 30s 32 + Productivity programs in Novartis Technical 31 Operations and Novartis Business Services

+ Resource allocation in commercial units

‒ Generic erosion

2017 2018 2019 near term medium ‒ Launch investments for potential future term blockbusters, including inclisiran

15 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Operational excellence Advancing deep transformations in NTO and NBS

Strategic levers NTO NBS

Organization Reduced ~1,800 FTEs across global functions and On track to reduce ~600 FTEs by 2022 site operations (net of site exits) Associates in NGSCs from <40% to >50% Footprint 10 sites exited Footprint reduction through sale, lease-back, and 9 additional exits announced Activity-Based Working (20+ offices) 102 out of 210 warehouses consolidated Moved to single service provider for REFS Procurement 28% reduction in suppliers for finished product, API New Chief Procurement Officer 45% reduction in suppliers for indirect materials Optimizing terms with top 100 suppliers Data & Digital Delivering advanced analytics solutions on asset, Continued investments in tech enablers material and inventory management Re-design of key enterprise processes

On track for ~USD 2bn savings by end of 2020; new efforts expected to deliver additional ~USD 1.5bn savings medium term

NTO – Novartis Technical Operations; Baseline EOY 2016 NBS – Novartis Business Services; Baseline EOY 2018 NGSCs – Novartis Global Service Centers API – Active pharmaceutical ingredients REFS – Real estate and facility services

16 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Operational excellence Sandoz delivered accretive growth in 2019 by implementing refined strategy

Sales growth (vs. PY, cc) Refined strategy

Geographic . EU: Solidifying #1 position GLOBAL +2% priorities . JP: Closing Aspen acquisition and investing . US: Stabilizing the business EX-US In the process of concluding oral solids +7% business divestment Launching pegfilgrastim Increasing +16% BIOPHARMACEUTICALS . Creating Sandoz TechOps organization autonomy

Core operating income growth (vs. PY, cc) Portfolio . Building biosimilar pipeline further - update trastuzumab / natalizumab deals . Appealing US Erelzi® decision +10% . Gx Advair® discontinued further development

17 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Go big on data and digital Four core elements to our digital transformation

Scale 12 digital Become the #1 partner Make Novartis digital Pursue bolder moves lighthouses in tech ecosystem

Spanning the entire value >1,500 associates mobilized Scale novel partnership Getting ready for disruptive chain, from development to accelerator: the Novartis healthcare scenarios through Rapidly build Data Science commercial operations and AI capabilities Biome large-scale alliances, e.g.: In full flight with 2-3 year Complement internal skills Microsoft: AI Innovation Lab Move to One Digital global . implementation horizon collaboration platform and capabilities . AWS1: TechOps optimization Investing in technology Closely linked to business Dedicated leadership . Tencent: Heart Failure platforms, including CRM, capability program priorities patient solution in China MDM, API

1. AWS: Amazon Web Services

18 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Unleash the power of our people Broad set of initiatives to drive culture change

Inspired Curious Unbossed Connect to our purpose Go big on learning Build leadership and provide an inspiring self-awareness and working environment capabilities

. Spark live to 83,000 associates, . Coursera: ~3,500 courses completed . 18 countries visited by CEO in 2019 1 230,000 recognitions given in 2019 by 7,000+ users (~85,000 hours) . Unbossed Leadership Experience . Minimum 14 weeks paid leave for all . LinkedIn Learning: ~14,000 courses (ULE) to be completed in 2020 for the parents, regardless of gender available, 12,500+ users1 top 300 leaders in the company

1. As of YE 2019

19 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Build trust with society In 2019, we made important progress on our efforts to build lasting trust with society

Ethical Standards Pricing & Access Global Health Corporate Citizenship

Rolled out globally the new Third Brought LIC & LMIC prices in Signed partnership for SCD Joined the UN Equal Pay Party Risk Management system line with EU5 average with the Government of Ghana International Coalition Drafting the new Code of Ethics, Outlined new access strategy Joined Global Chagas Disease Achieved 44% female co-created with our associates for Sub-Saharan Africa Coalition representation in management

20 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Build trust with society Introducing ambitious 2020 ESG targets which are deeply embedded in our operating model

Holistic set of ESG targets for 2020...... deeply embedded in our operating model Pillar Target Ethical Transparency on clinical trials Systematically reviewed Standards Strengthen Third Party Risk Management Tracked bi-monthly at the Trust & Reputation Fully integrate Human Rights into TPRM Committee, a sub-committee of the Executive Pricing Increase patient reach Committee of Novartis (ECN) chaired by the CEO & Access Enhance access Implement pricing principles Linked to compensation Global Malaria: Advance development of new drugs Cascaded into ECN personal objectives, and directly Health Sickle cell disease: Expand coverage impacting compensation Chagas: Progress on clinical trial Corporate Reduce energy & carbon Transparently disclosed Citizenship Reduce waste To be included in 2020 Annual Report, providing Reduce water disclosure on our goals and progress

21 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Build trust with society Bold long-term aspirations across the ESG spectrum

Select examples

Achieve carbon Reduce launch time lag neutrality in own to 3 months in LMICs operations by 2025

Implement access Deliver on UN EPIC strategy for advanced and LGBTI equity therapies in LMICs pledges

Transform treatment of Holistically address malaria with USD 100m sickle cell disease in committed in R&D1 Ghana

1. Commonwealth Heads of Government Meeting April 2018, commitment over the next 5 years LMICs – low and middle income countries www.novartis.com/nisreport2019

22 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation In-market growth drivers, major launches and a rich pipeline expected to sustain our long-term growth

. 15 ongoing / upcoming major launches . 80+ major submissions planned to 2022 New indications . 50+ late stage programs1 Cosentyx® HS Alpelisib PROS Novel assets Cosentyx® GCA Piqray® TNBC Cosentyx® LP Piqray® HER2+ aBC Inclisiran MBG453 Cosentyx® JIA Piqray® ovarian cancer Major launches TQJ230 Asciminib Cosentyx® LN Piqray® HNSCC LNP023 Canakinumab Entresto® post-AMI Kisqali® HR+/HER2- BC (adj) In-market Iscalimab Capmatinib Beovu® DME Kymriah® FL growth drivers Ligelizumab Spartalizumab Beovu® RVO AD portfolio2 177Lu-PSMA-617 Beovu® DR LNA043 Beovu® PDR Tropifexor Ofatumumab pediatric Ofatumumab AVXS-101 IT UNR844 QVM / QMF149

SELECT EXAMPLES

1. Ph3 / in registration 2. AD portfolio – atopic dermatitis portfolio incl. ZPL389, CEE321

23 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation 24 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Strong Pharmaceuticals growth driven by Cosentyx®, Entresto® and recent launches

Pharmaceuticals net sales USD billion, growth in % cc +12% Strong sales momentum driven by growth drivers +7% 23.3 . Mainly Cosentyx® and Entresto® 21.5 0.7 20.0 . Maintaining solid performance of established products 5.5 7.1 3.9 Focus on launches to deliver next phase of growth . Launched Zolgensma®, Beovu® and Mayzent® in US 16.1 16.0 15.5 . Xiidra® acquired and integrated into Ophtha franchise . Added inclisiran to CRM pipeline 2017 2018 2019

Key growth drivers1 Recent launches2 Established products3

CRM – Cardiovascular, Renal and Metabolism 1. Cosentyx®, Entresto®, Xolair®, Ilaris® 2. Zolgensma®, Xiidra ®, Aimovig®, Luxturna®, Mayzent® and Beovu® 3. All other brands

25 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Cosentyx® Q4 sales driven by strong demand and broad access across indications and regions

Cosentyx® sales evolution USD million Strong performance, above market . Q4 sales up +21% cc 3.6bn Ex-US . PsO TRx outperform market (+27% YoY vs. +12%)1 US . SpA TRx growing >2x faster than market2 2.8bn 937 965 858 806 750 791 Maintain momentum 701 . nr-axSpA submitted to FDA in Dec 580 . Pediatric PsO submitted to EMA in Nov . Expected to maintain broad access in 2020

Upgrading expected peak sales >USD 5bn Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2018 2019

1. IQVIA US National Prescription Audit for Dermatology WE 12/20/2019; market includes Enbrel®, Humira®, Siliq®, Skyrizi®, Stelara®, Taltz®, Tremfya® 2. IQVIA US National Prescription Audit for Rheumatology WE 12/20/2019; SpA market includes Cimzia®, Enbrel®, Humira®, Simponi®, Stelara®, Taltz® All trademarks are the property of their respective owners

26 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Entresto® solidifying leadership position in 2019 as an essential first-choice treatment in heart failure

Entresto® sales evolution USD million, cc Strong momentum . Q4 sales +65% driven by increased demand in hospital Ex-US 1.7bn US and ambulatory settings 518 . US TRx growth (+48% vs. PY) 1.0bn 421 430 357 318 271 Poised for further growth acceleration 239 200 . New data on reverse cardiac remodeling, in-hospital use and QoL . Inclusion on China NRDL, supporting expanded use

Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 . US regulatory submission for HFpEF on track for Q1 2018 2019 . Japan launch expected in H2

AHA – American Heart Association; QoL – Quality of Life; NRDL – National Reimbursement Drug List; HFpEF – Heart Failure with preserved Ejection Fraction

27 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Strong start to Beovu® US launch with excellent customer feedback and broad access

Strong uptake in 3 months since launch1 Broad access and reimbursement

of US retina specialists have permanent J-Code received, 84% Beovu® available in their office Jan 1 providing greater reimbursement confidence

of retina specialists who don’t positive benefits verification 90% currently use Beovu® plan to 95% outcomes to date2 use it in next 6 months

EU approval expected Q1 2020, JP approval expected Q2 2020

1. Novartis commissioned Retina Specialist Panel Online Survey, Dec 2019. 2. Covered or covered with restrictions

28 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Ofatumumab (OMB157) is poised to set a new standard for simple, broad and early B-cell therapy adoption

Unsurpassed efficacy and favorable safety supporting broad and early use in RMS

24 OMB 20mg 45.9% risk22 reduction (p<0.001) in 24-week CDW post-hoc . Regulatory file submitted in US and EU analyses with20 revisedTER definition14mg used in OPERA trials1 18 16 . Easy-to-use autoinjector available upon launch, 14 12 enabling simple at-home self-administration and 10 TER 10.5% 8 improved patient experience 6 HR (95% CI): 0.541 4 (0.381; 0.768) 2 OMB 5.6% . Strong scientific presence at major congresses

0 and in markets through 2020

M estimate of cumulative event rate [%] rateevent cumulative of estimate M

- K

0 3 6 9 12 15 18 21 24 27 . Engaging with payers on rapid, broad early Study month access

CDW – Confirmed Disability Worsening Source: ASCLEPIOS I & II data presentation available here 1. Adapted from the OPERA trials, Hauser et al. 2017. Different to the ASCLEPIOS study, a disability “progression” was defined as an increase from the baseline EDSS score of at least 1.0 point (or 0.5 points if the baseline EDSS score was >5.5) that was sustained for at least 12 (24) weeks, used in OPERA trials

29 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Inclisiran (KJX839), preparing to launch potentially transformative cholesterol-lowering therapy

Differentiated asset Preparing for launch

Efficacy Potent, durable, consistent LDL-C Organizational . MDCO now subsidiary of Novartis, expected to reduction >50% be fully integrated end March 2020

Safety Profile similar to placebo (no liver, Regulatory . US and EU files submitted1 muscle, renal nor platelet signals) . JP bridging program in progress in entire clinical program . CN local development aligned with CFDA Convenience Durable efficacy with only 2 subcutaneous injections per year, Commercial . Finalizing hiring and training of US teams less patient abandonment . Value-based pricing and flexible access strategy . Engaging with payers and health systems to Adherence Payers confidence reinforced by enable broad and affordable access, including physician administration dosing population models (e.g. UK NHS) regimen . Scaling up supply

1. Regulatory submissions filed by The Medicines Company

30 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Focus in 2020 will be launches and preparing for next big bets, building on the strong foundation

Prepare for next big bets

Deliver on new launches TQJ230: Lp(a) awareness and testing Beovu®: Global rollout and DME / Iscalimab: Educate on unmet need, RVO expansion leveraging transplant legacy Maximize growth drivers Ofatumumab: Broad and early Ligelizumab: Build US infrastructure access in CoEs and community Cosentyx®: nr-axSpA launch Tropifexor: Drive disease awareness Inclisiran: Broad & affordable access doubles addressable axSpA given asymptomatic nature of NASH population Mayzent®: Urgency to treat and LNP023: Educate physicians on patient services optimization Entresto®: NRDL-driven expansion complement-driven renal & in CN, JP approval expected Xiidra®: Return to growth hematologic diseases

31 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation 32 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Strong Oncology growth driven by recent launches and growth drivers

Oncology net sales USD billion, growth in cc +10% Potential future growth +9% 14.4 + Strong uptake of recent launches 13.4 1.3 12.3 0.5 + Growth drivers deliver double-digit performance 0.1 + Resource allocation/productivity to fuel strategic 2.5 3.3 3.9 investment (i.e. launches, China)

9.7 9.6 9.2 - Generic impact4 - Healthcare cost containment / pricing

2017 2018 2019

Key growth drivers1 Recent launches2 Established products3

1. Including Promacta®/Revolade®, Jakavi® (marketed by Novartis ex-USA), Tafinlar®+ Mekinist® 2. Including Kisqali®, Kymriah®, Lutathera®, Piqray®, Adakveo® 3. All other brands, including those with generic competition in the market 4. Afinitor®, Exjade®, Glivec® and Sandostatin® LAR in EU

33 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Accelerated sales and innovation reinforce the long-term growth of our breast cancer portfolio

2019 sales in USD m . ~40% of HR+/HER2- breast cancer patients have a PIK3CA mutation, associated with poor prognosis . NCCN guidelines updated, PIK3CA testing rate ~25% FY 2019 67 . Foundation Medicine PIK3CA CDx tissue approved Q4 2019, plasma 43 anticipated Q2 2020 6 . "EPIK" development program for 5 new indications1 with potential Q2 Q3 Q4 opportunity to serve an additional ~100k patients

. Only CDK 4/6 inhibitor that consistently demonstrated superior OS in 2 pivotal Phase 3 studies in 2019 155 111 123 . Early signs of OS accelerating US growth momentum in Q4 91 . Strong growth across key geographies ex-US in Q4 2019 . Potential registration for high and intermediate adjuvant BC as early as 2022 Q1 Q2 Q3 Q4 based pre-planned interim analysis (NATALEE, 3-year treatment duration)

1. TNBC, HER2+ aBC, ovarian cancer, HNSCC; alpelisib PROS

34 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Adakveo® is off to a solid start in US (approved Nov)

. The only approved monthly therapy for reduction in frequency of VOCs in SCD . Commercial product available within 2 days of approval . Payer engagement ongoing: – Community centers driving initial uptake SCD Patients in US 100K – Permanent J CODE anticipated July 2020 60% are 16yr old + 60K – Medicaid coverage criteria approved in Florida, Kentucky, Maryland, Washington, Delaware and Alabama 90% have >1 VOC + 54K

VOCs – Vaso-occlusive crises SCD – Sickle cell disease

35 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Maximizing momentum for our growth drivers and new launches, while preparing for next big bets

Prepare for next big bets

Capmatinib: Establish awareness of Deliver on new launches MET’s role in NSCLC among HCPs / patient community Maximize growth drivers Piqray®: Maximize US launch momentum Spartalizumab (PDR001) combo: Build and expand further to EU markets on Taf/Mek leadership position in ® metastatic melanoma Kisqali : Continued strong growth driven Adakveo®: Enable access in larger US by M3 and M7 OS data accounts and continue education and 177Lu-PSMA: Further evolve commercial Lutathera®: Leverage potential to grow in patient activation infrastructure for best in class launch earlier lines of treatment Kymriah®: Drive further capacity increase Canakinumab: Focus on medical Promacta®/Revolade®: Growth in ITP and to meet strong demand in pALL and education on tumor-promoting uptake in 1L SAA in the US and Japan DLBCL inflammation

36 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation 37 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation 2019 financial results in line with upgraded guidance

Group full year guidance (as revised in October 2019) FY 2019 vs. PY in cc in cc

“Sales expected to grow high single digit” 9% 

“Core operating income expected to grow mid to high teens” 17% 

38 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Strong sales growth drove double digit increases in core operating income and free cash flow

1 Change vs. PY Change vs. PY Continuing operations Q4 FY 2019 2019 USD million % USD % cc2 % USD % cc2 Net Sales 12,403 8 9 47,445 6 9

Core Operating income 2 3,462 11 13 14,112 12 17

Operating income 1,823 34 37 9,086 8 14

Net Income 1,129 -7 -6 7,147 -44 -41

Core EPS (USD)2 1.32 14 15 5.28 12 17

EPS (USD) 0.50 -6 -4 3.12 -43 -40

Free Cash Flow 2 3,488 20 12,937 15

1. Continuing operations excludes Alcon and includes the Sandoz US dermatology and oral solids portfolio business 2. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 58 of the Condensed Financial Report

39 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation 2019 free cash flow increased to USD 12.9bn driven by higher operating income

Continuing operations1 free cash flow2 USD billion +15% Key drivers vs. PY: + Higher operating income 12.9 11.3 (adjusted for non-cash items) Offsetting one-time effects: + Real estate divestment proceeds

− Prior year OTC JV dividend and GSK milestone income

2018 2019

1. Continuing operations excludes Alcon and includes the Sandoz US dermatology and oral solids portfolio business. 2. Free cash flow is a non-IFRS measures. An explanation of non-IFRS measures can be found on page 58 of the Condensed Financial Report

40 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Novartis proposes 23rd consecutive dividend increase to the AGM: 2.95 CHF / share1

2019 dividend yield 3.2% 2019 dividend growth 3.5%3

3.0

CHF USD

2.5

USD USD 3.04

CHF 2.95

CHF CHF 2.85 USD 2.84 2.0

1.5

1.0

0.5

0.0 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019

1. Proposal to shareholders at the 2020 Annual General Meeting, taking place on February 28, 2020 2. Converted at historic exchange rates at the dividend payment dates as per Bloomberg; assumes an exchange rate of USD/CHF of 0.9690 as of December 31, 2019 for 2019 3. In CHF

41 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Core margin expansion of +1.9%pts

Continuing operations

Q4 2019 FY 2019

Core operating Core margin 2 Net sales income 2 Core margin 2 Core margin 2 change vs. PY change vs. PY change vs. PY Core margin2 change vs. PY (%) (%pts cc)2 (in % cc) (in % cc) 2 (%) (%pts cc)2

Innovative Medicines 31.5 0.7 11 18 33.5 1.8

Sandoz 20.8 1.5 2 10 21.5 1.5

1 Continuing Operations 27.9 0.8 9 17 29.7 1.9

1. Continuing operations excludes Alcon and includes the Sandoz US dermatology and oral solids portfolio business. 2. Core results, constant currencies and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 58 of the Condensed Financial Report

42 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation 2020 Novartis full year guidance Barring unforeseen events; growth vs. PY in cc

Focused medicines company | full year guidance Excl. Sandoz US oral solids & dermatology businesses1

Sales expected to grow mid to high single digit . IM Division expected to grow mid to high single digit . Sandoz expected to grow low single digit

Core operating income expected to grow high single to low double digit

Key assumption: Guidance above includes the forecast assumption that no Gilenya® or Sandostatin® LAR generics enter in 2020 in US

1. The announced sale of Sandoz US dermatology and oral solids portfolio to Aurobindo, expected to close during Q1 2020. 2019 FY sales and core operating of the Sandoz US oral solids and dermatology businesses were approximately USD 1.1bn and 0.3bn, respectively.

43 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation FY 2020 Guidance on other financial KPIs Barring unforeseen events (in cc)

Focused medicines company | full year guidance Excl. Sandoz proposed US portfolio sale to Aurobindo1 from both 2019 and 2020

Core net Expenses expected to increase by around 0.2bn vs. 2019 reflecting financial result additional financing costs to acquire The Medicines Company

Core tax rate FY core tax rate expected to be broadly in line with 2019

44 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation 45 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Delivered strong performance in 2019

46 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation In-market growth drivers, major launches and a rich pipeline expected to sustain our long-term growth

SELECT EXAMPLES

1. Ph3 / in registration 2. AD portfolio – atopic dermatitis portfolio incl. ZPL389, CEE321

47 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Q&A session

Vas Narasimhan John Tsai Chief Executive Officer Head of Global Drug Development and CMO

Harry Kirsch Richard Saynor Chief Financial Officer CEO, Sandoz

Marie-France Tschudin Shannon Thyme Klinger President, Novartis Pharmaceuticals Group General Counsel

Susanne Schaffert President, Novartis Oncology

48 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Appendix Sales performance driven by Innovative Medicines

Key growth drivers Q4 Sales Growth vs. PY Growth vs. PY USD Million USD Million cc 518 200 65% 186 186 nm 965 159 21% 155 95 166% 90 90 nm 96 68 nm 67 67 nm 380 50 16% 356 43 15% 293 37 17% 303 35 16% Lutathera® 107 26 31% 178 23 16%

nm – not meaningful 50 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Expected currency impact for full year 2020

Currency impact vs. PY %pts, assuming late-January exchange rates prevail in 2020 FX impact on Net sales FX impact on Core operating income

-1 0 to -1 -1 to -2 -2 -1 to -2 -3 -3 -5 Q4 FY Q1 FY Q4 FY Q1 FY

2019 2020 2019 2020

Actual Simulation

51 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Net debt slightly reduced by USD 0.3bn in 2019 mainly driven by strong FCF

+0.3

-16.2 0.2 -15.9 2.9 -6.6 -3.8 -5.3 12.9 Dec 31, 2018 Dividends M&A transactions Treasury share Free Cash Flow1 Net debt Alcon2 Others Dec 31, 2019 transactions, net

1. Continuing operations excludes Alcon, includes the businesses of Innovative Medicines and Sandoz (including the US generic oral solids and dermatology portfolio), as well as the continuing corporate functions. 2. Includes the net de- recognition of USD 0.6bn cash and cash equivalents and USD 3.5bn of financial debts related to the Alcon spin-off.

52 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation 2019 pipeline milestones

H1 2019 H2 2019 ✓ Achieved* ✕ Missed* ®1 ® Regulatory Mayzent SPMS (US) ✓ BYL719 (Piqray ) HR+ Breast Cancer (US) ✓1 ® ® decisions and Kymriah Ped / Young Adult r/r ALL (JP) ✓ Beovu nAMD (US) ✓ ® ® opinions Kymriah r/r DLBCL (JP) ✓ Lucentis RoP (EU / JP) ✓ Promacta® Severe aplastic anaemia (EU) ✕ Lucentis® Diabetic Retinopathy (EU) ✓ Zolgensma® IV SMA (US) ✓ Mayzent® SPMS (EU / JP) ✓2 ® EU Q1 2020 ® Zolgensma IV SMA (EU / JP) JP H1 2020 Xolair Pollinosis (JP) ✓ ® Major Brolucizumab (RTH258) nAMD (US / EU / JP) ✓ Cosentyx nr-axSpA (US / EU / JP) ✓ ® expected Crizanlizumab (SEG101) Sickle Cell Disease (US / EU) ✓ Entresto HF-rEF (JP) ✓ Mayzent®1 SPMS (JP) ✓ Entresto® HF-pEF (US / EU) Q1 2020 submissions Capmatinib (INC280) NSCLC (US / JP) ✓ Ofatumumab (OMB157) Relapsing MS (US / EU) ✓3 PDR001 (combination Metastatic Melanoma (US / EU) H2 2020 with Tafinlar®+Mekinist®) QVM / QMF 149 Asthma (EU / JP) ✓ ® Major AVXS-101 IT SMA ✓ Cosentyx nr-axSpA ✓ ® ® 4 expected trial Zolgensma IV SMA presymptomatic ✓ Entresto HF-pEF (✓) Fevipiprant (QAW039) Asthma (✓)5 readouts Ofatumumab (OMB157) Relapsing MS ✓ PDR001 (combination Metastatic melanoma H2 2020 with Tafinlar® + Mekinist®)

*Represents achieving on-time readout of the data, irrespective of trial outcome 1. Piqray® FDA approval achieved in H1 2019. 2. Positive CHMP opinion Nov 2019, EMA approval Jan 2020 3. EU submission early January 2020 4. Study narrowly missed primary endpoint, but showed benefit in pre-specified large subgroups including women and patients with lower ejection fraction 5. LUSTER 1&2 readouts completed and did not meet the clinically relevant threshold for reduction in rate of moderate-to-severe exacerbation.

53 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation 2020 expected pipeline milestones

H1 2020 H2 2020 ✓ Achieved ✕ Missed Regulatory Beovu® nAMD (EU/JP) Adakveo® Sickle cell disease (EU) ® decisions and Cosentyx nr-axSpA (EU/US) Capmatinib (INC280) NSCLC (US/JP) ® ® opinions Cosentyx AS (CN) Cosentyx Pediatric psoriasis (EU) Ofatumumab (OMB157) Relapsing MS (US) Cosentyx® nr-axSpA (JP) HR+/HER2- aBC with PIK3CA Piqray® Entresto® HFpEF (US) mutation (EU) QVM149 Asthma (EU/JP) Inclisiran (KJX839) Hyperlipidemia (US) Tafinlar® & Mekinist® Adjuvant melanoma (CN) Xolair® Nasal Polyposis (US/EU) Xiidra® DED (EU) Zolgensma® IV SMA (JP/EU) Major Entresto® HFpEF (US) Alpelisib (BYL719) PROS (US) expected Inclisiran (KJX839) Hyperlipidemia (EU) ✓ AVXS-101 IT SMA (US) Juvenile PsA / enthesitis-related arthritis Cosentyx® submissions (US/EU) Spartalizumab (PDR001) Metastatic melanoma (US/EU) and Tafinlar® & Mekinist® 177Lu-PSMA-617 mCRPC (US) Entresto® Post-acute MI1 Asciminib (ABL001) CML 3L Major ® expected trial Tropifexor (LJN452) NASH Beovu DME readouts* UNR844 Presbyopia Jakavi® chronic GVHD Kisqali® aBC (MONALEESA-2 OS) 177Lu-PSMA-617 mCRPC

*Achieved = on-time readout of data, irrespective of trial outcome. 1. Interim analysis readout

54 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Capitalizing on the rich pipeline, faster and broader access in China

FY 2019 sales: 2019 2020 USD 2.2bn Achieved Planned

Cosentyx® Tasigna® Cosentyx® Pataday® Zykadia® NDA PsO Pediatric CML AS Allergic Conj. ALK+NSCLC 1st line Approval Gilenya® Tafinlar®+Mekinist® Mayzent® Tafinlar®+Mekinist® MS BRAF+ mM RMS Adj. Melanoma

® Afinitor Exelon® Patch Lucentis® Vigamox® Cosentyx® Tafinlar®+Mekinist® Votrient® TSC-SEGA and BRAF+ mM GI/LUNG NET AD DME/RVO/CNV Bacterial Conj. PsO aRCC NRDL Entresto® Exjade® Revolade® Xolair® Gilenya® Tasigna® Zykadia® Access Chronic HF IOL ITP Asthma MS Adult CML ALK+NSCLC 2nd line ® Eucreas® Jakavi® Ultibro® Sandostatin LAR Tasigna® Zykadia® Acromegaly and st T2D Myelofibrosis COPD GEP NET Pediatric CML ALK+NSCLC 1 line

55 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Building depth across our core therapeutic areas…

PHARMACEUTICALS ONCOLOGY CRM IHD Neuroscience Ophthalmology Respiratory

1 Select commercial

assets 2

Spartalizumab combo LNP023 LNA043 Ofatumumab (OMB157) UNR844 QVM149 Metastatic Melanoma Renal diseases Primary Osteoarthritis MS Presbyopia Asthma

177Lu-PSMA-617 TQJ230 Iscalimab (CFZ533) LMI070 ECF843 CSJ117 mCRPC CVRR Transplant / Sjögren's SMA Dry Eye Asthma

Canakinumab (ACZ885) Inclisiran (KJX839) Ligelizumab (QGE031) SAF312 QBW251 Select Lung Hyperlipidemia CSU / CIU Chronic Ocular Pain COPD

pipeline Asciminib (ABL001) Adriforant (ZPL389) assets CML AD MBG453 Tropifexor (LJN452) MDS, AML NASH

LOU064 CSU

CRM – Cardiovascular, Renal & Metabolism IHD – Immunology, Hepatology & Dermatology 1. Aimovig® is developed in collaboration with Amgen 2. Luxturna® marketed ex-US

56 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation ...while strengthening our innovative platforms

GENE THERAPY CELL THERAPY RADIO-LIGAND THERAPY

Select 1 commercial assets

Zolgensma® CPK850 CD19 CAR-T CD19 CAR-T 177Lu-PSMA-617 177Lu-PSMA-R2 SMA Retinis Pigmentosa DLBCL in 1st relapse r/r Follicular Lymphoma mCRPC Prostate Cancer

AVXS-101 IT CD19 CAR-T CD19 CAR-T 177Lu-NeoB SMA r/r DLBCL in combo with pembro Adult r/r ALL Various cancers

AVXS-201 CD19 CAR-T CD19 CAR-T Rett Syndrome r/r CLL in combo with ibrutinib Pediatric NHL

Select CD19 CAR-T AVXS-301 CD19 CAR-T 1st line high risk pediatric and pipeline ALS r/r DLBCL in combo with ibrutinib young adult ALL assets AVXS-401 CD19 CAR-T CD19 CAR-T Friedreich’s Ataxia BCMA&CD19 CD22&CD19

AVXS-501 CD19 CAR-T CD19 CAR-T Undisclosed CD123 EGFRv3

AVXS-601 Undisclosed

1. Luxturna® marketed ex-US Includes preclinical and launched programs

57 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Our pipeline projects at a glance

Phase 1/2 Phase 3 Registration Total ONCOLOGY 57 20 3 80

PHARMACEUTICALS 57 17 10 84 Cardiovascular, Renal, Metabolism 9 5 1 15 Immunology, Hepatology, Dermatology 22 6 2 30 Neuroscience 9 0 2 11 Ophthalmology 5 3 1 9 Respiratory 7 3 3 13 Global Health 5 0 1 6 BIOSIMILARS 0 1 0 1 Total 114 38 13 165

58 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Novartis submission schedule New molecular entity: lead and new indications

2020 2021 2022 2023 ≥2024

spartalizumab Lead asciminib Lead ECF843 Lead LOU064 Lead 177Lu-NeoB Lead LNA043 Lead CPK850 Lead TQJ230 Lead PDR001 ABL001 Dry eye Chronic spontaneous urticaria 177Lu-NeoB Osteoarthritis RP CVRR-Lp(a) m BRAF V600+ melanoma (+Taf/Mek) CML 3L Multiple Solid Tumors

177Lu-PSMA-617 Lead MBG453 Lead iscalimab Lead VPM087 Lead tropifexor Lead AVXS-201 Lead ganaplacide Lead 177Lu-PSMA-617 HR-MDS CFZ533 1st line CRC / 1st line RCC LJN452 OAV201 KAF156 mCRPC Renal/Liver Tx NASH Rett syndrome Malaria

ligelizumab Lead LNP023 Lead adriforant Lead tropifexor&cenicriviroc Lead LMI070 Lead cipargamin Lead QGE031 PNH ZPL389 LJC242 SMA KAE609 Chronic urticaria Atopic dermatitis NASH Malaria

CSJ117 Lead CEE321 Lead SAF312 Lead MIJ821 Lead LXE408 Lead Severe asthma Atopic Dermatitis COSP Depression Visceral leishmaniasis

denosumab BioS ianalumab Lead UNR844 Lead QBW251 Lead GP2411 VAY736 Presbyopia COPD

anti RANKL mAb AIH LEAD INDICATIONS

canakinumab LCM canakinumab LCM spartalizumab LCM capmatinib LCM MBG453 LCM LOU064 LCM LNP023 LCM ACZ885 ACZ885 PDR001 INC280 Unfit AML SjS iMN NSCLC 2L Adjuvant NSCLC Malignant melanoma (combo) Solid tumors

canakinumab LCM LNP023 LCM crizanlizumab LCM iscalimab LCM tropifexor LCM inclisiran LCM ACZ885 C3G SEG101 CFZ533 LJN452 LNP023 NSCLC 1L Sickle cell anaemia w ith crisis SjS NASH (combos) Hyperlipidemia

crizanlizumab LCM LNP023 LCM MBG453 LCM ianalumab LCM ofatumumab LCM cipargamin LCM SEG101 IgAN Fit AML VAY736 OMB157 KAE609 Sickle cell anaemia new formulations pSjS Ped MS Malaria

MBG453 LCM

AML NEW INDICATIONS

Compared to past reports, we have categorized submission schedules into NMEs (lead & new indications) and supplementary indications for existing brands

59 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Novartis submission schedule Supplementary indications for existing brands

2020 2021 2022 2023 ≥2024

alpelisib, BYL719 LCM Kymriah LCM Kisqali LCM Piqray LCM Piqray LCM Kymriah LCM Jakavi LCM Cosentyx LCM PROS tisagenlecleucel-T, CTL019 ribociclib, LEE011 alpelisib, BYL719 alpelisib, BYL719 tisagenlecleucel-T, CTL019 ruxolitinib, INC424 secukinumab, AIN457 r/r DLBCL 1st relapse HR+/HER2- BC (adj) TNBC HNSCC 2/3L 1L high risk ALL, pediatrics & young adults Pediatrics Chronic GVHD Lupus Nephritis

Cosentyx LCM Kymriah LCM Promacta LCM Piqray LCM Jakavi LCM Kymriah LCM Cosentyx LCM Cosentyx LCM secukinumab, AIN457 tisagenlecleucel-T, CTL019 eltrombopag, ETB115 alpelisib, BYL719 ruxolitinib, INC424 tisagenlecleucel-T, CTL019 secukinumab, AIN457 secukinumab, AIN457 Psoriasis 300mg AI r/r Follicular lymphoma Radiation sickness syndrome HER2+ adv BC Pediatrics Acute GVHD r/r DLBCL (+ pembro) GCA Ankylosing spondylitis

Cosentyx LCM Tafinlar LCM Cosentyx LCM Piqray LCM 177Lu-PSMA-R2 LCM Jakavi LCM Cosentyx LCM Mayzent LCM secukinumab, AIN457 dabrafenib, DRB436 secukinumab, AIN457 alpelisib, BYL719 177Lu-PSMA-R2 ruxolitinib, INC424 secukinumab, AIN457 siponimod, BAF312 PsA H2H Neoplasm Pedia SpA IVIV Ovarian cancer Prostate cancer Myelofibrosis (combination) Lichen Planus Ped MS

Cosentyx US LCM Promacta LCM Cosentyx LCM Kymriah LCM secukinumab, AIN457 eltrombopag, ETB115 secukinumab, AIN457 tisagenlecleucel-T, CTL019 Ped Psoriasis Food effect free formulation Hidradenitis suppurativa Adult r/r ALL

AVXS-101 LCM Jakavi LCM Cosentyx LCM Tafinlar LCM onasemno-gene abepar-vovec, OAV101 ruxolitinib, INC424 secukinumab, AIN457 dabrafenib, DRB436 SMA IT Chronic GVHD AS H2H Tyroid cancer

Xolair LCM Jakavi LCM Entresto EUa LCM Beovu LCM omalizumab, IGE025 ruxolitinib, INC424 valsartan+sacubitril, LCZ696 brolucizumab, RTH258 CSU (for CN) Acute GVHD Pediatric HF Diabetic retinopathy

Entresto LCM Beovu LCM Beovu LCM valsartan+sacubitril, LCZ696 brolucizumab, RTH258 brolucizumab, RTH258 HFpEF DME RVO

Xolair LCM omalizumab, IGE025 Food allergy

Xolair LCM omalizumab, IGE025 Auto-injector

Entresto LCM valsartan+sacubitril, LCZ696 Post-AMI

Lamprene LCM clofazimine, LAM320 Tuberculosis

a) Approved in US Compared to past reports, we have categorized submission schedules into NMEs (lead & new indications) and supplementary indications for existing brands

60 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Novartis pipeline in registration 6 lead indications Lead indication

Oncology Cardiovascular, Renal, Metabolism Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) PIK3CA mutant HR+, HER2 (-) postmenopausal adv BC5 2nd line KJX839 inclisiran siRNA (PCSK9) Hyperlipidemia BYL719 Piqray PI3Kα inhibitor (+fulv) INC280 capmatinib Met Inhibitor NSCLC SEG101 Adakveo® P-selectin Inhibitor Sickle cell disease Global Health Code Name Mechanism Indication(s) Immunology, Hepatology, Dermatology LAM320 Lamprene® SMPD1 Inhibitor Tuberculosis Code Name Mechanism Indication(s) AIN457 Cosentyx IL17A Inhibitor Ped Psoriasis nr-axSpA

Ophthalmology Code Name Mechanism Indication(s) RTH258 Beovu VEGF Inhibitor nAMD

Neuroscience Code Name Mechanism Indication(s) OAV101 Zolgensma® Gene therapy SMA IV OMB157 ofatumumab CD20 Antagonist r MS

Respiratory Disease Code Name Mechanism Indication(s) IGE025 Xolair IgE Inhibitor Nasal polyps QMF149 Indacaterol acetate Long acting b2-adrenergic Asthma +mometasone furoate agonist + inhaled corticosteroid QVM149 Indacaterol acetate Long acting b2-adrenergic Asthma +mometasone fuorate agonist + long-acting muscarinic +glycopyrrnium bromide antagonist + inhaled corticosteroid

61 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Novartis pipeline in Phase 3 5 lead indications Lead indication

Oncology Respiratory Disease Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) 177Lu-PSMA-617 177Lu-PSMA-617 Targeted Radioligand Therapy mCRPC IGE025 Xolair® IgE Inhibitor CSU (for CN) Auto-injector Food allergy ABL001 asciminib BCR-ABL Inhibitor CML 3L Adjuvant ACZ885 canakinumab IL-1b Inhibitor NSCLC 1L NSCLC 2L NSCLC BYL719 Piqray® PI3Kα inhibitor HER2+ adv BC TNBC HNSCC 2/3L Ovarian cancer CTL019 Kymriah CD19 CART r/r Follicular 1L high risk r/r DLBCL 1st Adult r/r ALL Cardiovascular, Renal, Metabolism lymphoma ALL, pediatrics relapse Code Name Mechanism Indication(s) and young adults KJX839 inclisiran siRNA (PCSK9) Hyperlipidemia ETB115 Promacta® Thrombopoietin receptor (TPO-R) Radiation sickness syndrome Food effect free formulation LCZ696 Entresto® AT-II / NEP,NEP,AGTR1,AGTR2 Inhibitor Post-AMI HFpEF Pediatric HFa Agonist TQJ230 TQJ230 Anti-Apo(a) ASO targeting Lp(a) CVRR-Lp(a) INC424 Jakavi JAK1/2 Inhibitor Acute GVHD Chronic GVHD LEE011 Kisqali® CDK4 Inhibitor HR+/HER2- BC (adj) PDR001 Spartalizumab PD1 Inhibitor m BRAF V600+ melanoma (+Taf/Mek) Biosimilars SEG101 crizanlizumab P-selectin Inhibitor Sickle cell anemia new formulation Code Name Mechanism Indication(s) GP2411 denosumab anti RANKL mAb Denosumab BioS

Immunology, Hepatology, Dermatology Code Name Mechanism Indication(s) AIN457 Cosentyx IL17A Inhibitor Lupus Psoriasis Hidradenitis AS H2H PsA H2H Nephritis 300mg AI suppurativa QGE031 ligelizumab IgE Inhibitor Chronic spontaneous urticaria

Ophthalmology Code Name Mechanism Indication(s) RTH258 Beovu® VEGF Inhibitor Diabetic retinopathy RVO DME

a) Approved in US

62 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Novartis pipeline in Phase 2 27 lead indications Lead indication

Oncology Neuroscience Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) ACZ885 canakinumab IL-1b Inhibitor Sickle cell anaemia AFQ056 AFQ056 mGluR5 Antagonist Addiction BYL719 alpelisib PI3Kα inhibitor PROS BAF312 Mayzent® S1P1 Modulator Ped MS Stroke CTL019 Kymriah CD19 CART r/r DLBCL (+ pembro) BLZ945 BLZ945 CSF-1 Inhibitor ALS EGF816 nazartinib+capmatinib Opdivo EGFR Inhibitor NSCLC LMI070 branaplam Survival motor neuron protein SMA INC280 capmatinib Met Inhibitor Solid tumors MIJ821 MIJ821 NR2B Inhibitor Depression Met Inhibitor + spartalizumab HCC NSCLC OMB157 ofatumumab CD20 Antagonist Ped MS INC424 Jakavi® JAK1/2 Inhibitor Myelofibrosis (combination) LAG525 LAG525 LAG3 Inhibitor Solid Tumors MBG453 MBG453 TIM3 Antagonist HR-MDS Unfit AML AML Fit AML NIR178 NIR178, spartalizumab Ad2AR Inhibitor, PD1 Inhibitor Cancers Respiratory Disease PDR001 spartalizumab PD1 Inhibitor Nasopharyngeal cancer Metastatic melanoma (combo) Code Name Mechanism Indication(s) SEG101 crizanlizumab P-selectin Inhibitor Ped sickle cell anaemia with ACZ885 canakinumab IL-1b Inhibitor Sarcoidosis crisis CJM112 CJM112 IL-17A Inhibitor Asthma CSJ117 CSJ117 TSLP Inhibitor Severe asthma Immunology, Hepatology, Dermatology LOU064 LOU064 BTK Inhibitor Asthma QBW251 QBW251 CFTR Potentiator COPD Code Name Mechanism Indication(s) VAY736 ianalumab BAFF-R Inhibitor IPF AIN457 Cosentyx® IL17A Inhibitor SpA IVIV GCA Lichen Planus CFZ533 iscalimab CD40 Inhibitor Renal/Liver Tx SjS HS T1DM LJC242 tropifexor&cenicriviroc CCR2 Inhibitor, FXR agonist NASH LJN452 tropifexor FXR agonist NASH Nash (combos) Cardiovascular, Renal, Metabolism LNA043 LNA043 ANGPTL3 Agonist Osteoarthritis Code Name Mechanism Indication(s) LOU064 LOU064 BTK Inhibitor Chronic spontaneous urticaria SjS CFZ533 iscalimab CD40 Inhibitor Lupus Nephritis LYS006 LYS006 Anti-inflammatory Acne LMB763 nidufexor FXR Agonist Diabetic Nephropathy VAY736 ianalumab BAFF-R Inhibitor AIH pSjS SLE LNP023 LNP023 CFB Inhibitor PNH IgAN C3G iMN ZPL389 adriforant HRH4 Antagonist Atopic dermatitis Global Health Ophthalmology Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) KAE609 cipargamin PfATP4 inhibitor Malaria Malaria severe CPK850 CPK850 RLBP1 AAV RP KAF156 ganaplacide - Malaria ECF843 ECF843 rh-Lubricin Dry eye LXE408 LXE408 Protozoan Inhibitor Visceral leishmaniasis LKA651 LKA651 EPO Inhibitor DME SAF312 SAF312 TRPV1 Antagonist COSP UNR844 UNR844 disulfide bonds Modulator Presbyopia

63 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Novartis pipeline in Phase 1 (1 of 2) 33 lead indications Lead indication

Oncology Code Name Mechanism Indication(s) 177Lu-NeoB 177Lu-NeoB Radioligand therapy target GRPR Multiple solid tumors 177Lu-PSMA-R2 177Lu-PSMA-R2 Radioligand therapy target PSMA Prostate cancer ADPT01 NIR178, LAG525, spartalizumab, canakinumab, capmatinib LAG3 Inhibitor,PD1 Inhibitor TNBC BLZ945 BLZ945 + spartalizumab CSF-1 Inhibitor + PD1 Inhibitor Solid tumors CSJ137 CSJ137 Growth Factor Inhibitor Anaemia CTL019 Kymriah® CD19 CART Lymphoma DKY709 DKY709 + spartalizumab - Cancers EGF816 nazartinib + LXH254, ribociclib, capmatinib, Opdivo, Mekinist EGFR Inhibitor NSCLC HDM201 HDM201 + MBG453, venetoclax MDM2 Inhibitor Haematological malignancy JEZ567 JEZ567 CD123 CART AML JJO686 JJO686 CD22 CART ALL LHC165 LHC165 + spartalizumab TLR7 Agonist Solid tumors LSZ102 LSZ102, ribociclib, alpelisib SERD BC LXF821 LXF821 EGFR CART, PD1 Inhibitor Glioblastoma multiforme LXH254 LXH254 (combos) cRAF Inhibitor Solid tumors Solid tumors MAK683 MAK683 EED Inhibitor Cancers MAS825 MAS825 - Inflammatory diseases MBG453 MBG453 (combos) TIM3 Antagonist Cancers MCM998 MCM998, LXG250 BCMA CART, CD19 CART Multiple myeloma MIK665 MIK665 MCL1 Inhibitor AML Haematological malignancy AML (combo) NIS793 NIS793, spartalizumab TGFB1 Inhibitor, PD1 Inhibitor Solid tumors NIZ985 NIZ985, spartalizumab IL-15 Agonist Solid tumors NJH395 NJH395 - Solid tumors NZV930 NZV930, spartalizumab, NIR178 CD73 Antagonist Solid tumors PDR001 spartalizumab, CJM112, LCL161 PD1 Inhibitor, TIM3 Antagonist AML Solid tumors (combo) Solid tumors (combo) Solid tumors (combo) SQZ622 SQZ622 CD123xCD3 Modulator AML TNO155 TNO155 SHP2 Inhibitor Solid tumors (single agent) Solid tumors (combo) VAY736 ianalumab + ibrutinib BAFF-R Inhibitor,BTK Inhibitor Haematological malignancy VOB560 VOB560 - Cancers VPM087 VPM087 IL1B Antagonist 1st line CRC / 1st line RCC WNT974 WNT974 + spartalizumab Porcupine Inhibitor Solid tumors WVT078 WVT078 - Multiple myeloma YTB323 YTB323 + ibrutinib CD19 CART Haematological malignancy

64 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Novartis pipeline in Phase 1 (2 of 2) 34 lead indications Lead indication

Immunology, Hepatology, Dermatology Code Name Mechanism Indication(s) DFV890 DFV890 - Multiple Indications LRX712 LRX712 - Osteoarthritis MHS552 MHS552 - Autoimmune Indications MHV370 MHV370 - SLE

Neuroscience Code Name Mechanism Indication(s) OAV101 AVXS-101 Survival motor neuron protein SMA IT 1 gene therapy OAV201 AVXS-201 MECP2 gene therapy Rett syndrome

Respiratory Disease Code Name Mechanism Indication(s) CMK389 CMK389 IL-18 Inhibitor Sarcoidosis

Cardiovascular, Renal, Metabolism Code Name Mechanism Indication(s) HSY244 HSY244 - Atrial fibrillation LTW980 LTW980 - Hypertriglyceridemia MBL949 MBL949 - Diabetes

Global Health Code Name Mechanism Indication(s) KAF156 ganaplacide - Malaria prophylaxis

1. FDA placed a partial hold on AVXS-101 intrathecal clinical trials for SMA patients based on findings in a small pre-clinical animal study

65 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Abbreviations

AIH Autoimmune hepatitis IT Intrathecal formulation ALL Acute lymphoblastic leukemia IV Intravenous formulation ALS Amyotrophic lateral sclerosis JIA Juvenile idiopathic arthritis AMI Acute myocardial infarction LP Lichen planus AML Acute myeloid leukemia LN Lupus nephritis AS H2H Ankylosing spondylitis head-to-head study versus adalimumab mCRPC Metastatic castration-resistant prostate cancer BC Breast cancer MDR Multi-drug resistant C3G C3 glomerulopathy MDS Myelodysplastic syndrome CDx Companion diagnostics MS Multiple sclerosis CCF Congestive cardiac failure nAMD Neovascular (wet) age-related macular degeneration CLL Chronic lymphocytic leukemia NASH Non-alcoholic steatohepatitis CML Chronic myeloid leukemia nr-axSpA Non-radiographic axial spondyloarthritis CRC Colorectal cancer NRDL National reimbursement drug list COPD Chronic obstructive pulmonary disease NSCLC Non-small cell lung cancer COSP Chronic ocular surface pain PDR Proliferative diabetic retinopathy CSU Chronic spontaneous urticaria PEF Preserved ejection fraction CVRR-Lp(a) Secondary prevention of cardiovascular events in patients with elevated levels of lipoprotein (a) PNH Paroxysmal nocturnal haemoglobinuria CVRR-LDLC Secondary prevention of cardiovascular events in patients with elevated levels of LDLC PsA H2H Psoriatic arthritis head-to-head study versus adalimumab DME Diabetic macular edema RCC Renal cell carcinoma DLBCL Diffuse large B-cell lymphoma refractory PROS PIK3CA related overgrowth spectrum FL Follicular lymphoma RA Rheumatoid arthritis GCA Giant cell arteritis rMS Relapsing multiple sclerosis GVHD Graft-versus-host disease ROP Retinopathy of prematurity HCC Hepatocellular carcinoma RP Retinitis pigmentosa HFpEF Chronic heart failure with preserved ejection fraction RVO Retinal vein occlusion HF-rEF Chronic heart failure with reduced ejection fraction SAA Severe aplastic anemia HNSCC Head and neck squamous cell carcinoma SjS Sjögren’s syndrome HS Hidradenitis suppurativa SLE Systemic lupus erythematosus IgAN IgA nephropathy SMA Spinal muscular atrophy type 1 (IV formulation) iMN Membranous nephropathy SpA Spondyloarthritis IOL Iron overload SPMS Secondary progressive multiple sclerosis ITP Immune thrombocytopenia TNBC Triple negative breast cancer IPF Idiopathic pulmonary fibrosis T1DM Type 1 Diabetes melitus

66 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Clinical Trials Update

Includes selected ongoing or recently concluded global trials of Novartis development programs/products which are in confirmatory development or marketed (typically Phase 2 or later). For further information on all Novartis clinical trials, please visit: www.novartisclinicaltrials.com Key changes vs. Q3-2019 presentation New trials added Study Program Indication Phase Patients NCT04156620 INVIGORATE-1 (CAIN457P12301) Cosentyx® Axial spondyloarthritis Phase 3 500 NCT04065841 ELIVATE (CLJN452D12201C) LJN452 Non-alcoholic steatohepatitis (NASH) Phase 2 210 NCT03373461 (CLNP023X2203) LNP023 IgA nephropathy Phase 2 146 NCT03439839 (CLNP023X2201) LNP023 Paroxysmal nocturnal hemoglobinuria Phase 2 15 NCT03832114 (CLNP023X2202) LNP023 C3 glomerulopathv Phase 2 27 NCT03896152 (CLNP023X2204) LNP023 Paroxysmal nocturnal hemoglobinuria Phase 2 10 NCT03955445 (CLNP023B12001B) LNP023 C3 glomerulopathy Phase 2 27 NCT04154787 (CLNP023D12201) LNP023 Idiopathic membraneous nephropathy Phase 2 72 NCT04109313 (CLOU064A2201E1) LOU064 Chronic spontaneous urticaria (CSU) Phase 2 250 NCT03988608 (CETB115E2202) Promacta®/ Previously untreated or relapsed/refractory severe aplastic anemia Phase 2 20 Revolade® or recurrent aplastic anemia NCT04047472 HOBBY (CRTH258A2307) RTH258 Macular degeneration Phase 3 494

Trials removed (operational decision-points achieved) Study Program Indication Phase Patients NCT02059291 CLUSTER (CACZ885N2301) Ilaris® Hereditary periodic fevers Phase 3 203 NCT03578367 ASC4MORE (CABL001E2201) ABL001 Chronic myeloid leukaemia (CML) Phase 2 80

68 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Cardiovascular, Renal and Metabolic Entresto® - Angiotensin receptor neprilysin inhibitor (ARNI)

Study NCT02678312 PANORAMA HF (CLCZ696B2319) NCT03785405 (CLCZ696B2319E1 – extension study) Indication Heart failure in pediatric patients Heart failure in pediatric patients

Phase Phase 2/3 Phase 3

Patients 360 240 Part 1: Pharmacodynamics and pharmacokinetics of Primary Outcome Number of participants with Adverse Events (AEs) and sacubitril/valsartan LCZ696 analytes Measures Serious Adverse Events (SAEs) Part 2: Efficacy and safety compared with enalapril • Part 1: Sacubitril/valsartan 0.8 mg/kg or 3.1 mg/kg or both; 0.4 mg/kg or 1.6 mg/kg or both (single doses). • Part 2: enalapril/placebo 0.2 mg/kg bid (ped. formulation • Single arm, open label sacubitril/valsartan (pediatric 1mg/ml) and adult formulation (2.5, 5, 10 mg bid); formulation granules (12.5, 31.25 mg in capsules); liquid Arms/Intervention Sacubitril/valsartan (LCZ696)/placebo: Ped. formulation formulation (1mg/ml and 4mg/ml concentration) and granules (12.5, 31.25 mg in capsules); liquid formulation adult formulation (50, 100, 200 mg bid)) (1mg/ml and 4mg/ml concentration) and adult formulation (50, 100, 200 mg bid) Pediatric patients from 1 month to < 18 years of age with Pediatric patients with heart failure due to systemic left Target Patients heart failure due to systemic left ventricle systolic ventricle systolic dysfunction who have completed study dysfunction CLCZ696B2319 H2-2021; (Analysis of 110 pts from Part 2 formed the basis for pediatric submission in Apr-2019 and approval by the US Expected Completion FDA in Oct-2019 for the treatment of symptomatic HF with 2022 systemic left ventricular systolic dysfunction in children aged 1 year and older) Publication TBD TBD

70 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Entresto® - Angiotensin receptor neprilysin inhibitor (ARNI) Study NCT02554890 PIONEER-HF (CLCZ696BUS01) NCT02661217 TRANSITION (CLCZ696B2401) Indication Heart failure, reduced ejection fraction Heart failure, reduced ejection fraction

Phase Phase 3B/4 Phase 4

Patients 881 1,002 Assessing the percentage of patients who achieve the target Primary Outcome Percentage change from baseline in N-terminal pro-brain dose of 200 mg bid LCZ696 at 10 weeks after Measures natriuretic peptide (NT-proBNP) randomization

• Sacubitril/valsartan (LCZ696) 24/26 mg, 49/51 mg or • Pre-discharge treatment initiation - LCZ696 (50, 100, 97/103 mg bid or matching placebo 200 mg bid) Arms/Intervention • Enalapril (2.5 mg, 5 mg, and 10 mg) bid or matching • Post-discharge treatment initiation - LCZ696 (50, 100, placebo 200 mg bid)

Patients with HFrEF (LVEF<40%) hospitalized for ADHF Heart failure patients with reduced ejection-fraction Target Patients and stable for more than 24 hours hospitalized for an acute decompensation event

Expected Completion Q3-2018 (actual) Q4-2018 (actual) • 28-May-2019 TRANSITION primary publication - • Mar-2019 ACC: 4wk OLE data, and core study data on published EJHF biomarkers, de novo HF, hospitalizations, & prior • Secondary data presentations: de novo HF and exposure ACEi/ARB naive sub-groups presented at ESC-HF Publication • Apr-2019 Circulation: Research letter on composite Congress in May 2019 and submitted to EJHF in Jun- endpoint (Circulation. 2019;139:00–00) 2019 (expected publication Q3-2019) • Q3-2019 ESC: Secondary abstracts submitted • Planned in Q4-2019: 26-weeks data presentation at • Planned in Q1-2020: RAAS naive and de novo HF ESC-2019 in Paris

71 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Entresto® - Angiotensin receptor neprilysin inhibitor (ARNI)

Study NCT02884206 PERSPECTIVE (CLCZ696B2320) NCT02468232 PARALLEL-HF (CLCZ696B1301) Indication Heart failure Heart failure, reduced ejection fraction

Phase Phase 3 Phase 3

Patients 592 225 Time to the first occurrence of the composite endpoint - Primary Outcome Change from baseline in the CogState Global Cognitive either cardiovascular (CV) death or heart failure (HF) Measures Composite Score (GCCS) hospitalization • Sacubitril/valsartan 50, 100, and 200 mg bid with • Sacubitril/valsartan 50 mg, 100 mg, 200 mg bid/placebo placebo of valsartan of enalapril Arms/Intervention • Valsartan 40, 80, and 160 mg bid tablets with placebo • Enalapril 2.5 mg, 5 mg, 10 mg bid / placebo of for sacubitril/valsartan sacubitril/valsartan

Patients with chronic heart failure with preserved ejection Japanese heart failure patients (NYHA Class II-IV) with Target Patients fraction reduced ejection fraction

Expected Completion 2022 Q1-2019 (actual); H1-2021 (open-label extension) Planned in H1-2020: Core study primary manuscript in Circ Publication TBD J

72 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Entresto® - Angiotensin receptor neprilysin inhibitor (ARNI)

Study NCT01920711 PARAGON-HF (CLCZ696D2301) NCT03066804 PARALLAX (CLCZ696D2302) Indication Heart failure, preserved ejection fraction Heart failure, preserved ejection fraction Phase Phase 3 Phase 3 Patients 4,822 2,577

Cumulative number of primary composite events of Change in NT-proBNP from baseline to week 12 Primary Outcome cardiovascular (CV) death and total (first and recurrent) HF and change in 6 minute walk distance (6MWD) from Measures hospitalizations baseline to Week 24

• Sacubitril/valsartan 50 mg, 100 mg and 200 mg bid and matching placebo • Sacubitril/valsartan or placebo 50 mg, 100 mg, and 200 • Enalapril 2.5 mg, 5 mg and 10 mg bid and matching Arms/Intervention mg bid placebo • Valsartan or placebo 40 mg, 80 mg, and 160 mg bid • Valsartan 40 mg, 80 mg, 160 mg bid and matching placebo

Heart failure patients (NYHA Class II-IV) with preserved Heart failure patients (NYHA Class II-IV) with preserved Target Patients ejection fraction ejection fraction

Expected Completion Q3-2019 (actual) Q4-2019 (actual) • Sep-2019: Primary manuscript published (Angiotensin– Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. Solomon S et al; NEJM. DOI: Publication TBD 10.1056/NEJMoa1908655) • Sep-2019: ESC: Late breaker presentation of primary results 73 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Entresto® - Angiotensin receptor neprilysin inhibitor (ARNI)

Study NCT03909295 (CLCZ696D1301E1 – extension study) NCT02924727 PARADISE-MI (CLCZ696G2301) Indication Heart failure chronic Post-acute myocardial infarction Phase Phase 3 Phase 3 Patients 63 5,650

Time to the first occurrence of a confirmed composite Primary Outcome Number of participants with Adverse Events (AEs) and endpoint (cardiovascular (CV) death, heart failure (HF) Measures Serious Adverse Events (SAEs) hospitalization, or outpatient heart failure)

• Sacubitril/valsartan 50 mg, 100 mg, 200 mg bid / placebo • Sacubitril/valsartan 50 mg,100 mg,200 mg film coated of ramipril/valsartan Arms/Intervention tablets • Ramipril 1.25 mg, 2.5 mg, and 5 mg bid / placebo of sacubitril/valsartan / placebo for valsartan

Japanese heart failure patients (NYHA Class II-IV) with Post-AMI patients with evidence of LV systolic dysfunction Target Patients preserved ejection fraction after CLCZ696D2301 and/or pulmonary congestion, with no known prior history of (PARAGON-HF) chronic HF

Expected Completion Q4-2019 (actual) H1-2021 Publication TBD TBD

74 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation LNP023 – Factor B inhibition of the complement alternative pathway

Study NCT03373461 (CLNP023X2203) NCT04154787 (CLNP023D12201) Indication IgA nephropathy (IgAN) Idiopathic membranous nephropathy (iMN) Phase Phase 2 Phase 2 Patients 146 72

Primary Outcome Change from baseline of log transformed UPCR derived Change from baseline of UPCR derived from 24hr urine Measures from the 24h urine collections at Baseline and Day 90 collections at Baseline and Week 24

• Placebo • LNP023 Dose 1 – 10mg bid • LNP023 Dose – 200mg bid Arms/Intervention • LNP023 Dose 2 – 50mg bid • LNP023 Dose – 50mg bid • LNP023 Dose 3 – 200mg bid • Rituximab • LNP023 Dose 4 – 100mg bid (Part 2 only)

Patients with biopsy proven iMN who are at high risk of Target Patients Patients with biopsy-verified IgA nephropathy disease progression defined on the basis of antibody anti- PLA2R titre and proteinuria

Expected Completion 2021 2022 Publication TBD TBD

75 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation LNP023 – Factor B inhibition of the complement alternative pathway

Study NCT03832114 (CLNP023X2202) NCT03955445 (CLNP023B12001B) Indication C3 glomerulopathy (C3G) C3 glomerulopathy (C3G) Phase Phase 2 Phase 2 (open-label extension) Patients 27 27 (from ongoing Phase 2, potential patient from Ph3) Cohort A: Ratio to Baseline of UPCR to Week 12 derived Characterize the effect of LNP023 treatment on a composite from 24hr urine collection renal response endpoint at 9 months (1. a stable or Primary Outcome Cohort B: Change from Baseline in C3 Deposit Score improved eGFR and, 2. a reduction in proteinuria and 3. an Measures (based on immunofluorescence microscopy) at Week 12 increase in C3 compared to the CLNP023X2202 baseline visit)

Increasing doses of LNP023 up to 200mg bid: Arms/Intervention • Cohort A: Native kidney patients • Open-label LNP023 200mg bid • Cohort B: Kidney transplanted patients

Target Patients Patients with C3 glomerulopathy Patients with C3 glomerulopathy

Expected Completion 2021 2025 Publication TBD TBD

76 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation LNP023 – Factor B inhibition of the complement alternative pathway

Study NCT03439839 (CLNP023X2201) NCT03896152 (CLNP023X2204) Indication Paroxysmal nocturnal hemoglobinuria (PNH) Paroxysmal nocturnal hemoglobinuria (PNH) Phase Phase 2 Phase 2 Patients 15 10

Reduction of PNH associated hemolysis, based on Primary Outcome Reduction of chronic hemolysis, based on LDH level at percentage of patients with 60% reduction in LDH or LDH Measures Week 13 below upper limit of normal up to 12 weeks of treatment.

• Cohort 1: 10 patients receiving LNP023 200mg bid, in addition to SoC, for 13 weeks with 3yr treatment extension • Arm 1: 4wks treatment LNP023 25mg bid followed by period 8wk treatment LNP023 100mg bid and 2yr extension • Cohort 2: 5 patients receiving LNP023 50mg bid, in LNP023 100mg bid Arms/Intervention addition to SoC, for minimum 2 weeks with 3yr treatment • Arm 2: 4wks treatment LNP023 50mg bid followed by extension period. Dose may be increased D15 onwards to 8wk treatment LNP023 200mg bid and 2yr extension 200mg bid if LDH not within limit of normal or reduced by at LNP023 200mg bid least 60% compared to Baseline.

Patients with PNH, showing signs of active hemolysis Patients with PNH, showing signs of active hemolysis, not Target Patients despite treatment with SoC (defined as an antibody with anti treated with any other complement inhibitor less than 3 C5 activity). months prior to study start Day 1

Primary endpoint: 2020 Primary endpoint: 2020 Expected Completion Extension period: 2023 Extension period: 2022 Publication In preparation TBD 77 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Immunology, Hepatology & Dermatology CFZ533 – Blocking, non-depleting, Fc-silent, anti-CD40 monoclonal antibody

Study NCT03663335 CIRRUS I (CCFZ533A2201) NCT03905525 TWINSS (CCFZ533B2201)

Indication Kidney transplantation Sjögren's syndrome

Phase Phase 2B Phase 2B

Patients 676 260

Composite event (BPAR, Graft Loss or Death) over 12 Change in EULAR Sjögren’s syndrome Disease Activity Primary Outcome months post-transplantation and post conversion (for Index (ESSDAI) score and EULAR Sjögren’s syndrome Measures maintenance cohort) Patient Reported Index (ESSPRI) score • Two cohorts: de novo TX and maintenance • Three dose arms of CFZ533 Arms/Intervention • Test Arms: CFZ533 + MMF + corticosteroids • Placebo • Standard of Care: TAC + MMF + corticosteroids Target Patients Kidney transplant recipients Patients with Sjögren's syndrome

Expected Completion 2022 2022

Publication Manuscript of PoC trial to be submitted in Q1-2020 Manuscript of PoC trial to be published in Q1-2020

79 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation CFZ533 – Blocking, non-depleting, Fc-silent, anti-CD40 monoclonal antibody

Study NCT03781414 CONTRAIL I (CCFZ533A2202)

Indication Liver transplantation

Phase Phase 2

Patients 128

Primary Outcome Proportion of patients with composite event (BPAR, Graft Measures Loss or Death) over 12 months

• Control/Standard of Care: TAC + MMF + Corticosteroids Arms/Intervention • CFZ533 dose A + MMF + Corticosteroids • CFZ533 dose B + MMF + Corticosteroids Target Patients Liver transplant recipients

Expected Completion 2022

Publication TBD

80 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Cosentyx® - Anti IL-17

Study NCT03504852 (CAIN457A2324) NCT03589885 MATURE (CAIN457A2325) Indication Psoriasis Psoriasis Phase Phase 3B Phase 3 Patients 331 122

Primary Outcome PASI 90 response and IGA mod 2011 0 or 1 response after PASI 75 response and IGA mod 2011 0 or 1 response after Measures 16 weeks of treatment 12 weeks of treatment

• Secukinumab 300 mg every 2 weeks after weekly doses • Secukinumab 2 mL (300 mg) auto-injector till Week 4 • Secukinumab 2 x 1 mL (150 mg each) prefilled syringe Arms/Intervention • Secukinumab 300 mg every 4 weeks after weekly doses • Placebo 2 mL auto-injector till Week 4 • Placebo 2 x 1 mL prefilled syringe

Target Patients Subjects (≥90kg) with moderate to severe plaque psoriasis Subjects with moderate to severe plaque psoriasis

Expected Completion Q3-2020 Q4-2020

Publication TBD TBD

81 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Cosentyx® - Anti IL-17

Study NCT02471144 (CAIN457A2310) NCT03668613 (CAIN457A2311) Indication Psoriasis Psoriasis Phase Phase 3 Phase 3 Patients 162 84 Psoriasis Area and Severity Index (PASI) 75 response and Psoriasis Area and Severity Index (PASI) 75 response and Primary Outcome Investigators' Global Assessment (IGA) 0 or 1 response at Investigators' Global Assessment (IGA) 0 or 1 response at Measures week 12 week 12

• Secukinumab low dose • Secukinumab high dose • Secukinumab low dose Arms/Intervention • Placebo • Secukinumab high dose • Etanercept (comparator)

Patients from 6 to less than 18 years of age with severe Pediatric patients of age 6 to <18 years, with moderate to Target Patients chronic plaque psoriasis severe plaque psoriasis Expected Completion 2023 2023

Publication TBD TBD

82 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Cosentyx® - Anti IL-17

Study NCT03066609 (CAIN457A2318) Indication Psoriasis

Phase Phase 3

Patients 543 Psoriasis Area and Severity Index (PASI) 75 response and Primary Outcome Investigators' Global Assessment (IGA) 0 or 1 response at Measures week 12

• Secukinumab 300 mg Arms/Intervention • Secukinumab 150 mg • Placebo

Patients with moderate to severe chronic plaque-type Target Patients psoriasis with or without psoriatic arthritis comorbidity

Expected Completion Q1-2019 (actual) • Week 16 results: Poster presented at: 2019 American Academy of Dermatology (AAD) Annual Meeting, Publication • March 1–5, 2019, Washington, D.C. • 52-week results: Poster at EADV 2019, Madrid 9-13 October, 2019

83 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Cosentyx® - Anti IL-17

Study NCT03031782 (CAIN457F2304) NCT03769168 (CAIN457F2304E1 – extension study) Indication Psoriatic arthritis Psoriatic arthritis Phase Phase 3 Phase 3 Patients 80 64

Primary Outcome Time to 33 flares Number of participants with JIA ACR30 response Measures

• Secukinumab (pre-filled syringe) 75 mg • Secukinumab 75 mg/0.5 ml Arms/Intervention • Placebo • Secukinumab 150 mg/1.0 ml

Juvenile idiopathic arthritis subtypes of psoriatic and Patients with juvenile idiopathic arthritis subtypes of juvenile Target Patients enthesitis-related arthritis psoriatic arthritis and enthesitis related arthritis Expected Completion H1-2021 2025

Publication TBD TBD

84 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Cosentyx® - Anti IL-17

Study NCT01892436 FUTURE 1 extension (CAIN457F2306E1) NCT01649375 MEASURE 2 (CAIN457F2310) Indication Psoriatic arthritis Ankylosing spondylitis Phase Phase 3 Phase 3 Patients 460 219 Proportion of subjects that have a positive clinical response Primary Outcome Assessment of SpondyloArthritis International Society / to treatment (individual improvement) in disease activity Measures ASAS 20 response according to ACR20 (or ACR50 or ACR 70)

• Secukinumab 75 mg • Secukinumab 75 mg Arms/Intervention • Secukinumab 150 mg • Secukinumab 150 mg • Placebo

Target Patients Patients with active psoriatic arthritis Patients with active ankylosing spondylitis Expected Completion Q1-2018 (actual) Q4-2018 (actual) • Primary 52 week results: Baeten D & Sieper J, et al. N Engl J Med 2015;373:2534–48 • 3 year results: ACR 2016; Mease PJ et al. Arthritis • 2 year results: Marzo-Ortega, et al. Arthritis Care Res Rheumatol. 2016; 68 (suppl 10) 2017 Feb 24. doi: - 10.1002/acr.23233 • 3 years results: Manuscript published in September • 3 year results: Marzo-Ortega, et al. RMD 2017 Publication 2018 (Mease PJ, et al. RMD Open 2018;4:e000723. • 5 year results: EULAR 2019; Marzo-Ortega H, et al. doi:10.1136/rmdopen-2018-000723) FRI0379. Annals of the Rheumatic Diseases • 5 year results: accepted for publication in ACR open 2019;78:873. Rheumatology in September 2019 • 5 year results; manuscript target submission Oct 2019

85 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Cosentyx® - Anti IL-17

Study NCT01752634 FUTURE 2 (CAIN457F2312) NCT02008916 MEASURE 3 (CAIN457F2314) Indication Psoriatic arthritis Ankylosing spondylitis Phase Phase 3 Phase 3 Patients 399 222

Primary Outcome Proportion of subjects achieving American College of Assessment of Spondyloarthritis International Society Measures Rheumatology 20 (ACR20) response criteria criteria / ASAS 20 response

• Secukinumab (AIN457) 150 mg s.c. • Secukinumab 10 mg/kg / 300 mg • Secukinumab (AIN457) 75 mg s.c. Arms/Intervention • Secukinumab 10 mg/kg / 150 mg • Secukinumab (AIN457) 300 mg s.c. • Placebo • Placebo s.c.

Target Patients Patients with active psoriatic arthritis Patients with active ankylosing spondylitis Expected Completion Q1-2019 (actual) Q1-2018 (actual) • 16 weeks results: PANLAR congress in Apr-2016 • Primary results: McInnes IB, et al. Lancet. • 52 weeks results: Pavelka et al. Arthritis Research & 2015;386:1137–46 Therapy 2017 • 2 years results: McInnes et al, Rheumatology • 2 year results: Presented at ACR in Nov-2017 Publication 2017;56:1993-2003 • 3 year (EOS) results: To be presented (ORAL) at • 5 year (EOS) manuscript ongoing; to be submitted in PANLAR April 2019 Oct-2019 • 3 year (EOS) manuscript submitted in May-2019; awaiting journal decision 86 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Cosentyx® - Anti IL-17

Study NCT01989468 FUTURE 3 (CAIN457F2318) NCT02159053 MEASURE 4 (CAIN457F2320) Indication Psoriatic arthritis Ankylosing spondylitis Phase Phase 3 Phase 3 Patients 416 350

Primary Outcome American College of Rheumatology 20 (ACR20) response in Assessment of Spondyloarthritis International Society Measures subjects treated with secukinumab vs. placebo criteria / ASAS 20 at week 16

• Secukinumab (AIN457) 150 mg s.c. • Secukinumab 150 mg s.c. with loading Arms/Intervention • Secukinumab (AIN457) 300 mg s.c. • Secukinumab 150 mg s.c. without loading • Placebo • Placebo

Target Patients Patients with active psoriatic arthritis Patients with active ankylosing spondylitis Expected Completion Q2-2018 (actual) Q2-2018 (actual)

52 week results: Nash et al, Arthritis Research & Therapy • Week 104 (EOS) manuscript: Kivitz et al, Rheumatol Publication 2018, 20:47 Ther https://doi.org/10.1007/s40744-018-0123-5

87 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Cosentyx® - Anti IL-17

Study NCT02294227 FUTURE 4 (CAIN457F2336) NCT02404350 FUTURE 5 (CAIN457F2342) Indication Psoriatic arthritis Psoriatic arthritis Phase Phase 3 Phase 3 Patients 342 990

Primary Outcome Assessment of American College of Rheumatology 20 American College of Rheumatology 20 (ACR20) response at Measures (ACR20) Week 16

• Secukinumab 150 mg load • Secukinumab 150 mg with loading • Secukinumab 150 mg no load Arms/Intervention • Secukinumab 150 mg without loading • Secukinumab 300 mg load • Placebo • Placebo

Target Patients Patients with active psoriatic arthritis Patients with active psoriatic arthritis Expected Completion Q1-2018 (actual) Q1-2019 (actual) • 24 week results published: Mease P, et al. Annals of the • 52 week results: abstract presented at PANLAR Rheumatic Diseases 2018;77:890-897. congress (Apr-2018) • 52 week results presented at EULAR and ACR 2018 Publication • 2 year (EOS) results published: Rheumatology • 52 week manuscript accepted (Rheumatology, October Therapy. 2019 Jun 21. doi: 10.1007/s40744-019-0163-5. 2019, in press) • 2 year (EOS) results presented at EULAR 2019

88 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Cosentyx® - Anti IL-17

Study NCT01863732 (CAIN457F2305E1 – extension study) NCT02745080 EXCEED (CAIN457F2366) Indication Ankylosing spondylitis Psoriatic arthritis Phase Phase 3 Phase 3 Patients 300 850

Primary Outcome Assessment of spondyloarthritis international society criteria American College of Rheumatology 20 (ACR20) response Measures / ASAS 20 response

• Secukinumab 75 mg in PFS • Secukinumab 300 mg s.c. Arms/Intervention • Secukinumab 150 mg in PFS • Adalimumab 40 mg s.c.

Target Patients Patients with active ankylosing spondylitis Patients with active psoriatic arthritis Expected Completion Q2-2018 (actual) Q1-2020 • 3-year results: Manuscript published in Clinical and Experimental Rheumatology in May-2017 • 4-year results: Presented at ACR in Nov-2017 • 4 year results manuscript published; Rheumatology, Publication Volume 58, Issue 5, May 2019, Pages 859–868, • Manuscript target submission Jan-2020 • 5 year (EOS) results manuscript published; Baraliakos X, et al. RMD Open 2019;5:e001005. doi: 10.1136/rmdopen-2019-001005

89 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Cosentyx® - Anti IL-17

Study NCT02696031 PREVENT (CAIN457H2315) NCT03259074 SURPASS (CAIN457K2340)

Indication Non-radiographic axial spondyloarthritis Ankylosing spondylitis

Phase Phase 3 Phase 3

Patients 555 837

The proportion of participants who achieved an ASAS 40 No radiographic structural progression as measured by Primary Outcome response (Assessment of SpondyloArthritis International modified Stoke Ankylosing Spondylitis Spine Score Measures Society criteria); (mSASSS) • Secukinumab 150 mg load • Secukinumab 150/300 mg Arms/Intervention • Secukinumab 150 mg no load • Adalimumab biosimilar 40 mg • Placebo

Target Patients Patients with non-radiographic axial spondyloarthritis Patients with active ankylosing spondylitis

Expected Completion Week 52: Q3-2019 (actual); Final: H1-2021 2022

• Abstract (16 week results) submitted as a late breaker to Publication ACR 2019 TBD • Manuscript target submission Jan-2020

90 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Cosentyx® - Anti IL-17

Study NCT03713619 SUNSHINE (CAIN457M2301) NCT03713632 SUNRISE (CAIN457M2302)

Indication Hidradenitis Suppurativa (HS) Hidradenitis Suppurativa (HS)

Phase Phase 3 Phase 3

Patients 471 471

Primary Outcome Proportion of participants with Hidradenitis Suppurativa Proportion of patients with Hidradenitis Suppurativa Clinical Measures clinical response (HiSCR) Response (HiSCR)

• Secukinumab 300 mg every 2 weeks • Secukinumab 300 mg every 2 weeks • Secukinumab 300 mg every 4 weeks • Secukinumab 300 mg every 4 weeks Arms/Intervention • Placebo (every 2 weeks) • Placebo (every 2 weeks) • Placebo (every 4 weeks) • Placebo (every 4 weeks) Target Patients Subjects with moderate to severe Hidradenitis Suppurativa Subjects with moderate to severe Hidradenitis Suppurativa

Expected Completion H2-2021 H2-2021

Publication Preliminary results in EADV (most likely) in 2021 Preliminary results in EADV (most likely) in 2021

91 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Cosentyx® - Anti IL-17

Study NCT04156620 INVIGORATE-1 (CAIN457P12301)

Indication Axial spondyloarthritis

Phase Phase 3

Patients 500

The proportion of subjects achieving an ASAS40 Primary Outcome (Assessment of SpondyloArthritis International Society Measures criteria) response

• Secukinumab intravenous (i.v.) regimen Arms/Intervention • Placebo intravenous (i.v.) regimen

Target Patients Patients with active axial spondyloarthritis

Expected Completion 2022

Publication TBD

92 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Ilaris® - Anti IL-1β

Study NCT02296424 (CACZ885G2306) Indication SJIA - Systemic Juvenile Idiopathic Arthritis Phase Phase 3B/4 Patients 182 Proportion of patients in clinical remission on canakinumab who are able to remain in remission Primary Outcome following canakinumab dose tapering (reduced Measures canakinumab dose or prolonged canakinumab dosing interval) • Canakinumab dose reduction Arms/Intervention • Canakinumab dose interval prolongation Patients with Systemic Juvenile Idiopathic Arthritis (SJIA) Target Patients (Pediatric) Expected Completion 2018 (actual)

• Remission & flexible dosing – presented at ISSAID & EULAR in Q2-2019 Publication • Planned manuscript in 2019: Remission & flexible dosing to be submitted in Q4-2019

93 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation LJN452 - FXR Agonist

Study NCT02855164 (CLJN452A2202) NCT04065841 ELIVATE (CLJN452D12201C) Indication Non-alcoholic steatohepatitis (NASH) Non-alcoholic steatohepatitis (NASH)

Phase Phase 2 Phase 2

Patients 345 210 Adverse event profile of different doses; determine the dose relationship of LJN452 on markers of hepatic inflammation Proportion of patients with resolution of NASH and no Primary Outcome in NASH (ALT and AST); determine dose-response worsening of fibrosis OR improvement in fibrosis by at least Measures relationship of LJN452 on liver fat content by changes in one stage without worsening of NASH at Week 48 quantitative MRI; determine effect of LJN452 on liver fibrosis compared with baseline by biopsy • Arm A: combination therapytropifexor + licogliflozin • Arm B: tropifexor monotherapytropifexor (+ licogliflozin Arms/Intervention • Multiple LJN452 doses and placebo placebo) • Arm C: licogliflozin monotherapylicogliflozin (+ tropifexor placebo) Adult patients with non-alcoholic steatohepatitis (NASH) Target Patients Patients with non-alcoholic steatohepatitis (NASH) and liver fibrosis Expected Completion Q2-2020 2022 • Primary (interim) data abstract submitted to AASLD in Publication Q3-2019 TBD • Manuscript to be submitted in H2-2020

94 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation LOU064 – Bruton's tyrosine kinase (BTK) inhibitor

Study NCT03926611 (CLOU064A2201) NCT04109313 (CLOU064A2201E1)

Indication Chronic spontaneous urticaria (CSU) Chronic spontaneous urticaria (CSU)

Phase Phase 2 Phase 2

Patients 308 250

Change from baseline in weekly Urticaria Activity Score (UAS7) at Week Primary Outcome Measures • Long-term safety and tolerability 4

• Arm 1 Low dose of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85 • Arm 2 Medium dose of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85 • Arm 3 High dose of LOU064 orally in the morning (once daily) and • Selected dose of LOU064 taken orally twice a day Arms/Intervention matching placebo in the evening from Day 1 to 85 (morning and evening) from day 1 to week 52 • Arm 4 Low dose of LOU064 orally, twice daily from Day 1 to 85 • Arm 5 Medium dose of LOU064 orally, twice daily from Day 1 to 85 • Arm 6 High dose of LOU064 orally, twice daily from Day 1 to 85 • Placebo arm Matching placebo, orally, twice daily from Day 1 to 85 Patients with CSU who have participated in preceding Target Patients Adults with CSU inadequately controlled by H1-antihistamines studies with LOU064 Expected Completion Q3-2020 2022

Publication TBD TBD

95 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation LJC242 - FXR agonist + CCR2/CCR5 inhibitor

Study NCT03517540 TANDEM (CLJC242A2201J)

Indication Non-alcoholic steatohepatitis

Phase Phase 2

Patients 200

• Evaluation of safety and tolerability of combination Primary Outcome therapy (tropifexor + cenicriviroc) by monitoring adverse Measures event profile, vital signs and laboratory parameters

• Tropifexor Arms/Intervention • Cenicriviroc • Tropifexor + cenicriviroc Adult patients with non-alcoholic steatohepatitis (NASH) and Target Patients liver fibrosis Expected Completion Q4-2020

Publication Manuscript to be submitted in H1-2021

96 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation QGE031 - Anti-IgE Study NCT02477332 (CQGE031C2201) NCT02649218 (CQGE031C2201E1)

Indication Chronic spontaneous urticaria / Chronic idiopathic urticaria Chronic spontaneous urticaria / Chronic idiopathic urticaria

Phase Phase 2B Phase 2B

Patients 382 226

Establish dose-response relationship of QGE031 with Primary Outcome Long-term safety; number of participants with treatment- respect to achievement of complete hives response at week Measures emergent adverse events 12 • Ligelizumab 24mg q4wks for 20 weeks • Ligelizumab 72mg q4wks for 20 weeks • Ligelizumab 240mg q4wks for 20 weeks Arms/Intervention Ligelizumab 240 mg q4wks open label for 52 weeks • Ligelizumab 120mg single dose • Omalizumab 300mg q4wks for 20 weeks • Placebo q 4wks for 20 weeks

Adult patients with chronic spontaneous urticaria Adult patients with chronic spontaneous urticaria inadequately controlled with H -antihistamines at approved inadequately controlled with H -antihistamines at approved Target Patients 1 1 or increased doses, alone or in combination with H2- or increased doses, alone or in combination with H2- antihistamines or leukotriene receptor antagonists. antihistamines or leukotriene receptor antagonists.

Expected Completion 2017 (actual) Q3-2019 (actual) • Primary results: Presented at EAACI 2018, EADV 2018, • Primary results: AAD 2019; and GUF 2018; NEJM publication (Oct. 3rd); • Secondary results presented in 2019 at: AAD, EAACI, Publication • Secondary results presented in 2019 at: AAD, EAACI, WCD, EADV, PAAM, ACAAI, UCARE; manuscript WCD, EADV, PAAM, ACAAI, UCARE. planned in H1/2020

97 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation QGE031 - Anti-IgE

Study NCT03437278 (CQGE031C2202)

Indication Chronic spontaneous urticarial / Chronic idiopathic urticaria

Phase Phase 2

Patients 48

Primary Outcome Change in the 7 day Urticaria Activity Score (UAS7) Measures

• Ligelizumab high dose q4wks for 24 weeks Arms/Intervention • Ligelizumab low dose q4wks for 24 weeks • Placebo / ligelizumab high dose q4wks for 8 / 16 weeks Adolescents from 12 to <18 years of age, with chronic Target Patients spontaneous urticaria Expected Completion H2-2021 • Study design was presented at PAAM (Peds Allergy & Asthma Meeting) and at UCARE meeting 2019 Publication • Primary results to be presented in 2022 (e.g. EAACI, PAAM, EADV) • Manuscript to be submitted in 2022

98 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation QGE031 - Anti-IgE

Study NCT03580369 Pearl 1 (CQGE031C2302) NCT03580356 Pearl 2 (CQGE031C2303)

Indication Chronic spontaneous urticaria Chronic spontaneous urticaria

Phase Phase 3 Phase 3

Patients 1,050 1,050

Primary Outcome Absolute change from baseline in UAS7 (Urticaria Activity Absolute change from baseline in UAS7 (Urticaria Activity Measures Score) at week 12 Score) at week 12

• Ligelizumab dose A q4w for 52 weeks • Ligelizumab dose A q4w for 52 weeks • Ligelizumab dose B q4w for 52 weeks • Ligelizumab dose B q4w for 52 weeks Arms/Intervention • Omalizumab 300 mg q4w for 52 weeks • Omalizumab 300 mg q4w for 52 weeks • Placebo q4w from randomization to wk20, then • Placebo q4w from randomization to wk20, then ligelizumab dose B from wk24 to wk52 ligelizumab dose B from wk24 to wk52 Adolescents and adults with chronic spontaneous urticaria Adolescents and adults with chronic spontaneous urticaria Target Patients inadequately controlled with H1-antihistamines inadequately controlled with H1-antihistamines Expected Completion H2-2021 H2-2021 • Study design presented at UCARE 2018 Publication • Primary results to be presented in 2022 (e.g. EAACI, PAAM, EADV) • Manuscript to be submitted in 2022

99 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation VAY736 – Fully human IgG1/κ anti-BAFF-R mAb

Study NCT02962895 (CVAY736A2201) NCT03217422 AMBER (CVAY736B2201)

Indication Primary Sjögren's syndrome Autoimmune hepatitis

Phase Phase 2B Phase 2/3

Patients 180 80

Primary Outcome Safety and efficacy of VAY736 in primary Sjögren's Alanine aminotransferase (ALT) normalization Measures syndrome (pSS)

• VAY736 • VAY736 Arms/Intervention • Placebo • Placebo control with conversion to active VAY736 Patients with moderate to severe primary Sjögren's Autoimmune hepatitis patients with incomplete response or Target Patients syndrome (pSS) intolerant to standard treatment of care Expected Completion Q2-2020 2023 • Late Breaking Abstract to be submitted to American Publication College of Rheumatology 30-Sep-2019 TBD • Manuscript to be submitted in 2020

100 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation ZPL389 - H4 receptor antagonist

NCT03948334 ZESTExt (CZPL389A2203E1 – extension Study NCT03517566 ZEST (CZPL389A2203) study)

Indication Atopic dermatitis Atopic dermatitis

Phase Phase 2 Phase 2

Patients 360 360

Primary Outcome Frequency of Adverse Events (AEs) and Serious Adverse IGA (Investigator's global assessment) response at week 16 Measures Events (SAEs)

• ZPL389 dose 1 • ZPL389 Dose 1 + Topical Corticosteroids (TCS) and /or • ZPL389 dose 2 Topical Calcineurin Inhibitors (TCI) Arms/Intervention • ZPL389 dose 3 • ZPL389 Dose 2 + Topical Corticosteroids (TCS) and /or • ZPL389 dose 4 Topical Calcineurin Inhibitors (TCI) • Placebo Target Patients Patients with moderate to severe atopic dermatitis Adult patients with atopic dermatitis

Expected Completion H1-2021 2023

Publication TBD TBD

101 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Neuroscience Zolgensma® - SMN1 gene replacement therapy

Study NCT03461289 STRIVE-EU (CL-302) NCT03306277 STRIVE (CL-303) Indication Type 1 spinal muscular atrophy Type 1 spinal muscular atrophy

Phase Phase 3 Phase 3

Patients 30 20

• Achievement of independent sitting for at least 30 Primary Outcome Proportion of participants sitting without support seconds Measures • Event-free survival

Arms/Intervention Open-label, single-arm, single-dose, intravenous Open-label, single-arm, single-dose, intravenous

Target Patients Patients with spinal muscular atrophy Type 1 Patients with Spinal Muscular Atrophy Type 1

Expected Completion H2-2020 Q4-2019 (actual)

Publication TBD TBD

103 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Zolgensma® - SMN1 gene replacement therapy

Study NCT03505099 SPR1NT (CL-304) NCT03837184 STRIVE Asia Pacific (CL-306) Indication Spinal muscular atrophy Type 1 spinal muscular atrophy

Phase Phase 3 Phase 3

Patients 27 6 • Percentage of participants achieving functional Primary Outcome independent sitting for at least 30 seconds at any visit Proportion of participants sitting without support Measures • Percentage of participants achieving the ability to stand without support for at least 3 seconds at any visit

Arms/Intervention Open-label, single-arm, single-dose, intravenous Open-label, single-arm, single-dose, intravenous

Pre-symptomatic patients with spinal muscular atrophy and Target Patients Patients with spinal muscular atrophy Type 1 multiple copies SMN2 Expected Completion H2-2021 H2-2021

Publication TBD TBD

104 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Zolgensma® - SMN1 gene replacement therapy

Study NCT03381729 STRONG (CL-102) Indication Type 2 spinal muscular atrophy

Phase Phase 1

Patients 27

• Safety and tolerability, incidence of adverse events Primary Outcome • Proportion of patients achieving Standing Milestone Measures • Change in Hammersmith Functional Motor Scale

Arms/Intervention Open-label, single-arm, single-dose, intrathecal

Target Patients Patients with spinal muscular atrophy with 3 copies of SMN2

Expected Completion Q4-2019 [Cohort B]

Publication TBD

105 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Aimovig® – CGRP receptor antagonist

Study NCT03096834 LIBERTY (CAMG334A2301) NCT03333109 EMPOWER (CAMG334A2302) Indication Migraine Migraine

Phase Phase 3 Phase 3

Patients 246 900

Primary Outcome Percentage of patients with a 50% response in the reduction Change from baseline in monthly migraine days at the last Measures of Monthly Migraine Days (MMD) month (Month 3) of the double-blind treatment period

• AMG334 (erenumab) Dose 1 • Subcutaneous injection of AMG334 (erenumab) Arms/Intervention • AMG334 (erenumab) Dose 2 • Subcutaneous injection of placebo • Placebo

Adult episodic migraine patients who have failed prophylactic Target Patients Adult episodic migraine patients migraine treatments

Expected Completion 2017 DBT phase (actual); H1-2021 OLE phase (final DBL) Q2-2020 • Planned for Q1-2020 (Neurology): PROs and prespecified subgroup analysis (DBT phase) Publication • Planned for Q2-2020: 1Y OLE Planned for H2-2020 • Planned for Q4 2020: 2Y OLE – TBC. Potentially abstract only 106 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Aimovig® – CGRP receptor antagonist

Study NCT03867201 DRAGON (CAMG334A2304) Indication Migraine

Phase Phase 3

Patients 550

Primary Outcome Change from baseline in monthly migraine days during the Measures last 4 weeks of the 12-week treatment period

• Subcutaneous injection of AMG334 (erenumab) 70 mg Arms/Intervention • Subcutaneous injection of placebo

Target Patients Adult chronic migraine patients

Expected Completion 2022 DBT phase; 2024 OLE phase

Publication Planned in Q4-2023 (DBT)

107 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Gilenya® - S1P-R modulator

Study NCT01633112 ASSESS (CFTY720D2312) NCT01201356 LONGTERMS (CFTY720D2399)

Indication Relapsing remitting multiple sclerosis (RRMS) Relapsing multiple sclerosis (RMS)

Phase Phase 3B Phase 3

Patients 1,064 4,125 Comparison of 2 doses (0.25 mg and 0.5 mg) of fingolimod Primary Outcome to glatiramer acetate (20 mg) in reducing the annualized Long-term safety and tolerability Measures relapse rate up to 12 months • Fingolimod 0.5 mg orally Arms/Intervention • Fingolimod 0.25mg orally Single-arm study of fingolimod 0.5 mg/day • Copaxone® 20 mg s.c.

Target Patients Patients with relapsing-remitting multiple sclerosis Patients with relapsing multiple sclerosis

Expected Completion 2018 (actual) 2018 (actual) • Cohen J et al. Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS • Primary data presentation at AAN in 2019 Publication study results (Therapeutic Advances in Neurological • Primary manuscript – submission planned in Q4-2019 Disorders 2019.12:eCollection 2019, doi: 10.1177/1756286419878324)

108 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation LMI070 - SMN2 RNA splice modulator

Study NCT02268552 (CLMI070X2201)

Indication Type 1 spinal muscular atrophy

Phase Phase 1/2

Patients 39

Primary Outcome Number of participants with adverse events (AEs), serious Measures adverse events (SAEs) and deaths

Branaplam oral, once weekly: • Part 1: 5 ascending doses Arms/Intervention • Part 2: 2 different dose levels • Part 3: patients continue on initial dose assigned in Part 1 or Part 2 Patients with type 1 spinal muscular atrophy Target Patients

Expected Completion Q3-2020

Publication TBD

109 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Mayzent ® - S1P-R modulator

Study NCT01665144 -EXPAND (CBAF312A2304) Indication Secondary progressive multiple sclerosis Phase Phase 3 Patients 1,652

The delay in time to confirmed disability progression as Primary Outcome Measures measured by EDSS (Expanded Disability Status Scale)

• BAF312 (5-day titration: 0.25mg to 1.25mg; Maintenance Arms/Intervention dose: 2mg (day 6)) • Placebo

Target Patients Patients with secondary progressive multiple sclerosis

Expected Completion Core in 2016/Extension in 2023

The Lancet Neurology, Volume 39, No.10127, p1237-1330, Publication March 2018

110 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation OMB157 - Anti-CD20

Study NCT02792218 Asclepios I (COMB157G2301) NCT02792231 Asclepios II (COMB157G2302) Indication Multiple sclerosis Multiple sclerosis

Phase Phase 3 Phase 3

Patients 900 900

Annualized Relapse Rate (ARR) - number of confirmed Annualized Relapse Rate (ARR) - number of confirmed Primary Outcome relapses in a year calculated based on cumulative number relapses in a year calculated based on cumulative number Measures of relapses by patient adjusted for time-in-study by patient of relapses by patient adjusted for time-in-study by patient

• Ofatumumab subcutaneous • Ofatumumab subcutaneous Arms/Intervention • Teriflunomide oral • Teriflunomide oral

Target Patients Patients with relapsing forms of multiple sclerosis Patients with relapsing forms of multiple sclerosis

Expected Completion Q3-2019 (actual) Q3-2019 (actual)

Publication Primary manuscript planned in H1-2020 Primary manuscript planned in H1-2020

111 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation OMB157 - Anti-CD20

Study NCT03249714 APOLITOS (COMB157G1301) NCT03650114 ALITHIOS (COMB157G2399) Indication Multiple sclerosis Multiple Sclerosis

Phase Phase 2 Phase 3

Patients 60 2010

Reduced cumulative number of Gd-enhanced T1 lesions Evaluate the long-term safety and tolerability of ofatumumab Primary Outcome across 4 MRI scans at week 12, 16, 20 and 24 (ofatumumab 20 mg subcutaneous (sc) once every 4 (q4) weeks in Measures vs placebo) subjects with RMS from the first dose of ofatumumab

• Ofatumumab 20 mg subcutaneous injections Arms/Intervention • Ofatumumab 20 mg every 4 weeks • Placebo

Target Patients Patients with relapsing forms of multiple sclerosis Patients with relapsing MS

Expected Completion Q1-2020 2025

Publication TBD TBD

112 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Oncology ABL001 – Specific, allosteric Bcr-Abl kinase inhibitor

Study NCT03106779 ASCEMBL (CABL001A2301)

Indication Chronic myeloid leukaemia (CML)

Phase Phase 3

Patients 233

Primary Outcome Major Molecular Response (MMR) rate at 24 weeks Measures

• ABL001 40 mg bid Arms/Intervention • Bosutinib 500 mg

Patients with chronic myelogenous leukemia in chronic Target Patients phase, previously treated with 2 or more tyrosine kinase inhibitors

Expected Completion H2-2020

Publication Manuscript submission in H2-2020 (journal TBD)

114 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation ACZ885 – IL-1β inhibitor

Study NCT03447769 CANOPY-A (CACZ885T2301) NCT03631199 CANOPY-1 (CACZ885U2301)

Indication Adjuvant NSCLC 1st Line Non-small cell lung cancer (NSCLC)

Phase Phase 3 Phase 3

Patients 1,500 627 • Safety run-in part: Incidence of dose limiting toxicities Primary Outcome Disease free survival (primary), overall survival (key • Double-blind, randomized, placebo-controlled part: Measures secondary) Progression free survival (PFS) • Overall survival (OS) • Canakinumab or matching placebo in combination with • Canakinumab 200mg q3w sc for 18 cycles Arms/Intervention pembrolizumab and platinum-based doublet • Placebo q3w sc for 18 cycles chemotherapy Patients with: Patients with • High–risk NSCLC (AJCC/UICC v.8 stage II-IIIA and IIIB • Histologically confirmed Stage IIIB, IV NSCLC with no Target Patients (T>5cm N2)) after complete resection and standard of prior systemic anticancer therapy care adjuvant cisplatin-based chemotherapy • Squamous and non-squamous NSCLC • All histologies • No EGFR mutation and ALK rearrangement

Expected Completion 2022 H1-2021 Johnson B et al. Abstract accepted for presentation at Publication TBD AACR-NCI-EORTC Oct 2019 (safety run-in)

115 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation ACZ885 – IL1β inhibitor

Study NCT03626545 CANOPY-2 (CACZ885V2301)

Indication 2nd / 3rd Line Non-small cell lung cancer (NSCLC)

Phase Phase 3

Patients 240

• Safety run-in part: Incidence of dose limiting toxicities Primary Outcome • Double-blind, randomized, placebo-controlled part: Measures Overall Survival

• canakinumab in combination with docetaxel Arms/Intervention • canakinumab matching-placebo in combination with docetaxel

Patients with: • Stage IIIB or IV NSCLCwithout EGFR, ALK, ROS-1 or B- Target Patients RAF mutation • Previously treated with platinum therapy and PD(L)1- inhibitor

Expected Completion H1-2021

Publication TBD

116 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation BYL719 - Alpha-specific PI3K inhibitor

Study NCT02437318 SOLAR-1 (CBYL719C2301) Indication HR+/HER2- advanced breast cancer with PIK3CA mutation Phase Phase 3 Patients 572

Primary Outcome Progression-free survival (PFS) for patients with PIK3CA Measures mutant status

• Fulvestrant 500 mg + alpelisib 300 mg Arms/Intervention • Fulvestrant 500 mg + placebo

Men and postmenopausal women with hormone receptor Target Patients positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment

Expected Completion Q3-2018 (actual) • Andre F, et al. Presentation at ESMO 2018 Publication • Andre et al. Manuscript N Engl J Med 2019;380:1929- 1940.

117 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Exjade® - Iron chelation of bis-hydroxy-phenyl triazole type

Study NCT00940602 TELESTO (CICL670A2302)

Indication Iron overload

Phase Phase 2

Patients 224

To compare deferasirox to placebo with regard to event-free Primary Outcome survival in low and int-1 risk MDS patient with transfusional Measures iron overload

• Deferasirox, iron chelator Arms/Intervention • Placebo

Patients with myelodysplastic syndromes (low/int-1 risk) and Target Patients transfusional iron overload

Expected Completion Q3-2018 (actual) • Angelucci E, et al. Presentation at ASH 2018 Publication • Angelucci E, et al. Manuscript submitted Q3-2019

118 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation INC280 - MET Inhibitor

Study NCT02414139 (CINC280A2201) NCT03647488 (CINC280D2201) EGFR Wild-type, ALK negative advanced Non-small Cell Indication Non-small cell lung cancer Lung Cancer (NSCLC) Phase Phase 2 Phase 2 Patients 364 105 Run in part: Assess safety and tolerability of capmatinib and Primary Outcome Overall Response Rate (ORR) spartalizumab combination. Measures Randomized part: Overall Survival (OS)

• Pre-treated pts. with MET GCN: ≥ 6; ≥ 4 and < 6; < 4 • Pre-treated pts. with MET mutations regardless of cMET GCN as second or third line • Capmatinib plus spartalizumab Arms/Intervention • Treatment-naïve pts. with MET dysregulation • Docetaxel • Pre-treated pts with MET dysregulation – second line • Treatment-naïve pts with cMET mutations regardless of cMET GCN

Pre-treated adult patients with EGFR wild-type ALK Adult patients with EGFR wild-type (wt), ALK-negative rearrangement negative advanced/metastatic non-small cell Target Patients advanced/ metastatic NSCLC with either MET lung cancer, that has demonstrated progression following one amplification or MET mutations prior platinum doublet and one prior PD-(L)1 checkpoint inhibitor Expected Completion Q2-2019 (actual) 2022 • Wolf J, et al. Presented at ASCO 2019 Publication TBD • Wolf J, et al. Manuscript submitted Q3-2019

119 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Jakavi® - JAK1/2 inhibitor

Study NCT02913261 REACH2 (CINC424C2301) NCT03112603 REACH3 (CINC424D2301) Indication Steroid-refractory acute graft vs. host disease (SR aGVHD) Steroid-refractory chronic graft vs. host disease (SR cGVHD)

Phase Phase 3 Phase 3

Patients 308 324 Primary Outcome Overall Response Rate (ORR) at 28 Days Overall Response Rate (ORR) at 183 Days Measures

• Ruxolitinib 10mg bid • Ruxolitinib 10mg bid Arms/Intervention • Best available therapy (BAT) • Best available therapy (BAT)

Target Patients Patients with SR aGVHD Patients with SR cGVHD

Expected Completion Q3-2019 (actual) Interim Analysis: Q3-2019 (actual); Final: Q3-2020 • Manuscript submission in Q4-2019 • Manuscript submission in H2-2020 Publication • Zeiser R, et al. Abstract submitted Q4-2019 • Abstract submission to congress in H2-2020

120 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Jakavi® - JAK1/2 inhibitor

Study NCT03491215 REACH4 (CINC424F12201) NCT04097821 ADORE (CINC424H12201) Indication Acute graft versus host disease Myelofibrosis

Phase Phase 2 Phase 1/2

Patients 45 130 • Incidence of dose limiting toxicities within the first 2 Primary Outcome • Measurement of PK parameters cycles Measures • Overall Response Rate (ORR) • Response rate at the end of cycle 6 • Ruxolitinib • Ruxolitinib+Siremadlin Arms/Intervention • Ruxolitinib • Ruxolitinib+Crizanlizumab • Ruxolitinib+MBG453 Pediatric patients with grade II-IV acute graft vs. host disease Target Patients Patients with Myelofibrosis (MF) after allogeneic hematopoietic stem cell transplantation

Expected Completion 2023 2024

Publication TBD TBD

121 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Kisqali® - CDK 4/6 inhibitor

Study NCT03701334 NATALEE (CLEE011O12301C) Adjuvant treatment of hormone receptor (HR)-positive, Indication HER2-negative, early breast cancer (EBC) Phase Phase 3 Patients ~4,000

Invasive Disease-Free Survival for using STEEP criteria Primary Outcome (Standardized Definitions for Efficacy End Points in adjuvant Measures breast cancer trials)

• Ribociclib + endocrine therapy Arms/Intervention • Endocrine therapy

Pre and postmenopausal women and men with HR-positive, Target Patients HER2-negative EBC, after adequate surgical resection, who are eligible for adjuvant endocrine therapy

Expected Completion Interim Analysis: H1-2021; Final: 2026 Publication TBD

122 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Kymriah® – CAR-T therapy

Study NCT02445248 JULIET (CCTL019C2201) NCT03568461 ELARA (CCTL019E2202) Indication Relapsed / refractory DLBCL Relapsed / refractory follicular lymphoma (FL) Phase Phase 2 Phase 2 Patients 128 113

Primary Outcome Overall response rate; efficacy and safety of CTL019 Complete Response Rate (CRR) Measures

Arms/Intervention Single-arm study of single dose of CTL019 Single-arm study of tisagenlecleucel

Adult patients with relapsed or refractory diffuse large B-cell Target Patients Adult patients with relapsed or refractory FL lymphoma (DLBCL)

Expected Completion 2017 (actual) Interim Analysis: Q3-2020 • Schuster et al. Presentations at ICML 2017; at EHA 2017; at ASH 2017; at ASH 2018; Borchmann et al. Presentation at EHA 2018; Bachanova et al. Publication TBD Presentation at ICML 2019 • Schuster et al. N Engl J Med. 2019;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.

123 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Kymriah® – CAR-T therapy

Study NCT03876769 CASSIOPEIA (CCTL019G2201J) NCT03570892 BELINDA (CCTL019H2301) Indication 1st line high risk acute lymphoblastic leukemia (ALL) 2nd line Diffuse large B-cell lymphoma (DLBCL) Phase Phase 2 Phase 3 Patients 160 318

Primary Outcome 5 year Disease Free Survival (DFS) Event-free Survival (EFS) Measures

Arms/Intervention Single-arm study of tisagenlecleucel; retreatment allowed Tisagenlecleucel versus standard of care Adult patients with aggressive B-cell Non-Hodgkin Target Patients Pediatric and young adult patients with 1st line high risk ALL Lymphoma after failure of rituximab and anthracycline- containing frontline immunochemotherapy Expected Completion 2025 H2-2021

Publication TBD TBD

124 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation MBG453 – TIM-3 antagonist

Study NCT03946670 STIMULUS MDS-1 (CMBG453B12201) Indication Myelodysplastic syndrome Phase Phase 2 Patients 120

Primary Outcome Complete Remission (CR) rate and Progression Free Measures Survival (PFS)

• Experimental: MBG453 + hypomethylating agents Arms/Intervention • Placebo comparator: Placebo + hypomethylating agents Adult subjects with intermediate, high or very high risk Target Patients Myelodysplastic Syndrome (MDS) as per IPSS-R criteria

Expected Completion H2-2021

Publication TBD

125 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation PDR001 – PD-1 checkpoint inhibitor

Study NCT02967692 COMBI-i (CPDR001F2301)

Indication BRAFV600 mutant metastatic melanoma

Phase Phase 3 538 Patients Part 1 (safety-run in): 9; Part 2 (biomarker cohort): 27; Part 3 (Phase III, randomized, placebo controlled): 532

Primary Outcome Progression-Free Survival (PFS) Measures

• Spartalizumab 400mg i.v. Q4W + Tafinlar 150mg bid + Arms/Intervention Mekinist 2 mg • Placebo + Tafinlar 150 mg bid + Mekinist 2 mg Previously untreated patients with unresectable or Target Patients metastatic BRAF V600 mutant melanoma

Expected Completion Q3-2020 Publication Abstract submission to congress in H2-2020

126 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Rydapt®- Multi-targeted kinase inhibitor

Study NCT03280030 (CPKC412A2220) NCT03591510 (CPKC412A2218) Indication Acute myeloid leukemia Acute myeloid leukemia Phase Phase 2 Phase 2 Patients 66 50

Primary Outcome Occurrence of dose limiting toxicities Incidence of safety events and event free survival Measures Event Free Survival ( EFS)

• Midostaurin 50 mg Arms/Intervention • Chemotherapy followed by Midostaurin • Placebo

Newly diagnosed patients with FLT3-mutated acute myeloid Newly diagnosed pediatric patients with FLT3 mutated acute Target Patients leukemia (AML) from pan-Asia countries myeloid leukemia (AML)

Expected Completion H1-2020 H2-2022

Publication Abstract submission to congress in H2-2020 TBD

127 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation PDR001 - PD-1 checkpoint inhibitor

Study NCT03484923 (CPDR001J2201) Indication Previously treated unresectable or metastatic melanoma

Phase Phase 2

Patients 230

Primary Outcome Objective Response Rate (ORR) Measures

• PDR001 400mg i.v. Q4W + LAG525 600 mg i.v. Q4W • PDR001 400mg i.v. Q4W + capmatinib 400 mg bid orally • PDR001 400mg i.v. Q4W + canakinumab 300 mg (s.c) Arms/Intervention Q4W • PDR001 400mg i.v. Q4W + ribociclib 600 mg p.o QD on Days 1 to 21 of a 28-day cycle

Adult patients with previously treated unresectable or Target Patients metastatic melanoma

Expected Completion H2-2021 Publication TBD

128 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Promacta®/Revolade® – Thrombopoetin receptor agonist

Study NCT03025698 (CETB115E2201) NCT03988608 (CETB115E2202) Previously untreated or relapsed/refractory severe aplastic Previously untreated or relapsed/refractory severe aplastic Indication anemia or recurrent aplastic anemia anemia or recurrent aplastic anemia Phase Phase 2 Phase 2 Patients 60 20

Primary Outcome PK of eltrombopag at steady state in pediatric patients with Hematologic response rate Measures SAA

• Eltrombopag 12.5, 25, 50, 75 mg FCT & 25 mg pFOS • Arm B: previously untreated SAA-hATG/cyclosporine + eltrombopag Arms/Intervention • Eltrombopag 25 mg film-coated tablets • Arm A: relapsed/refractory SAA or AA: hATG/cyclosporine + eltrombopag or cyclosporine + eltrombopag

Pediatric patients from age 1 <18 years with Chinese patients with refractory or relapsed severe aplastic Target Patients relapsed/refractory SAA or recurrent AA after IST or anemia previously untreated SAA

Expected Completion 2025 2023

Publication TBD TBD

129 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation SEG101 – p-Selectin inhibitor

Study NCT03264989 SOLACE-Adults (CSEG101A2202) NCT03474965 SOLACE-Kids (CSEG101B2201) Prevention of Vaso-Occlusive Crises (VOC) in patients with Indication Prevention of VOC in pediatric patients with SCD Sickle Cell Disease (SCD) Phase Phase 2 Phase 2

Patients 55 100

Primary Outcome PK/PD and safety of SEG101 (crizanlizumab) at 5 mg/kg PK/PD and safety of SEG101 at 5 mg/kg Measures

SEG101 (crizanlizumab) at a dose of 5.0 mg/kg (or 7.5 SEG101 (crizanlizumab) at a dose of 5 mg/kg by IV infusion Arms/Intervention mg/kg for exploratory group) by IV infusion, ± ± Hydroxyurea/Hydroxycarbamide Hydroxyurea/Hydroxycarbamide

Target Patients Adult SCD patients with VOC Pediatric SCD patients with VOC

H2-2021 (pediatric patients ≥6 year old) Expected Completion Q4-2018 (actual) 2022 (pediatric patients 6 months – 6 year old) Publication Abstract submission to congress in H1-2020 TBD

130 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation SEG101 – p-Selectin inhibitor

Study NCT03814746 STAND (CSEG101A2301) Prevention of Vaso-Occlusive Crises (VOC) in patients with Indication Sickle Cell Disease (SCD) Phase Phase 3

Patients 240

Primary Outcome Rate of VOC events leading to healthcare visit Measures

• Crizanlizumab 5.0 mg/kg Arms/Intervention • Crizanlizumab 7.5 mg/kg • Placebo

Target Patients Adolescent and adult SCD patients (12 years and older)

Expected Completion H1-2022

Publication TBD

131 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Tafinlar® - BRAF inhibitor

Study NCT01677741 (CDRB436A2102)

Indication BRAFV600 mutant cancers

Phase Phase 1/2

Patients 85

Primary Outcome Safety, tolerability and pharmacokinetics Measures

Single-arm study of oral dabrafenib (dose based on age Arms/Intervention and weight)

Pediatric subjects aged 1 year to <18 years with advanced Target Patients BRAF V600-mutation positive solid tumors

Expected Completion Q3-2020 • Kieran MW et al. Manuscript Clin Cancer Res; (accepted Q3-2019, not yet published) (PK analysis) Publication • Hargrave D et al. Manuscript Clin Cancer Res; (accepted Q3-2019, not yet published) (safety/efficacy in low-grade gliomas)

132 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Tafinlar®+Mekinist® - BRAF inhibitor and MEK inhibitor

Study NCT02684058 (CDRB436G2201) Indication BRAFV600 mutant gliomas

Phase Phase 2

Patients 142

Primary Outcome Objective response rate Measures

Arms/Intervention Dabrafenib + trametinib (dose based on age and weight)

Children and adolescent patients with BRAF V600 mutation Target Patients positive relapsed or refractory high grade glioma (HGG) or BRAF V600 mutation positive low grade glioma (LGG) Expected Completion H2-2021

Publication TBD

133 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Tafinlar®+Mekinist® - BRAFV600 inhibitor and MEK inhibitor

Study NCT02124772 (CTMT212X2101)

Indication BRAFV600 mutant solid tumors

Phase Phase 1/2A

Patients 142

Primary Outcome Safety, tolerability and pharmacokinetics and clinical activity Measures

Trametinib (dose based on age and weight) Arms/Intervention Dabrafenib + trametinib (dose based on age and weight)

Pediatric Subjects Aged 1 Month to <18 Years with Target Patients Advanced V600-Mutation Positive Solid Tumors

Expected Completion H1-2021

Publication Abstract submission to congress in H1-2020

134 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Zykadia® - ALK inhibitor

Study NCT02299505 ASCEND-8 (CLDK378A2112)

Indication ALK activated NSCLC

Phase Phase 2

Patients 306

Primary Outcome Part 1: Pharmacokinetics when taken with food Measures Part 2: Overall Response Rate (ORR) when taken with food

• Oral LDK378 450 mg once daily taken with food Arms/Intervention • Oral LDK378 600 mg once daily taken with food • Oral LDK378 750 mg once daily fasted

Adult patients with ALK-rearranged (ALK-positive) advanced non-small cell Target Patients lung cancer

Part 1 (PK): 2016 (actual) Expected Completion Part 2 (ORR): Q2-2018 (actual) Final (ORR): Q4-2019 • Part 1 (PK): Cho BC, et al. J Thorac Oncol. 2017 Sep; 12(9) 1357-1367 Publication • Part 2 (ORR): Cho B et al. J Thorac Oncol. 2019 Jul; 14(7) 1255-1265 • Final (ORR): TBD

135 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation 177Lu-PSMA-617 – Lu-labelled prostate specific membrane antigen (PSMA)

Study NCT03511664 VISION (PSMA-617-01) PSMA-positive Metastatic Castration-resistant Prostate Indication Cancer (mCRPC) Phase Phase 3

Patients 814

Primary Outcome • Radiographic Progression Free Survival Measures • Overall Survival

• 177Lu-PSMA-617 plus BS/BSC Arms/Intervention • BS/BSC alone

Adult patients with PSMA-positive Metastatic Castration- Target Patients resistant Prostate Cancer (mCRPC)

Expected Completion H2-2020

Publication TBD

136 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Ophthalmology Lucentis® - Anti-VEGF

Study NCT02375971 RAINBOW (CRFB002H2301) NCT02640664 RAINBOW Extension (CRFB002H2301E1) Indication Retinopathy of Prematurity (ROP) Retinopathy of Prematurity (ROP) Phase Phase 3 Phase 3 Patients 224 180

Absence of active Retinopathy of Prematurity (ROP) and unfavorable structural outcome at Week 24, defined as, 1) To evaluate the visual function of patients by assessing the Primary Outcome survival, 2) no intervention with a second modality for ROP, visual acuity in the better-seeing eye at the patient’s fifth Measures 3) absence of active ROP and 4) absence of unfavorable birthday. structural outcome

• Ranibizumab 0.2 mg (up to 3 injections max) • Ranibizumab 0.2 mg (up to Week 40, if warranted) Arms/Intervention • Ranibizumab 0.1 mg (up to 3 injections max) • Ranibizumab 0.1 mg (up to Week 40, if warranted) • Laser therapy

Male and female preterm infants with bilateral retinopathy of Male and female preterm infants with bilateral retinopathy of Target Patients prematurity (ROP) who require treatment. prematurity (ROP) who completed RAINBOW. Expected Completion Q1-2018 (actual) 2023 • EURETINA: Sep-2018 • AAO: Oct-2018 • Primary manuscript published online by The Lancet in Publication TBD Sep-2019 (https://www.thelancet.com/pdfs/journals/lancet/PIIS0140 -6736(19)31344-3.pdf) 138 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation RTH258 - Anti-VEGF

Study NCT02434328 HARRIER (CRTH258A2302) NCT02307682 HAWK (CRTH258A2301) Indication Neovascular age-related macular degeneration (nAMD) Neovascular age-related macular degeneration (nAMD)

Phase Phase 3 Phase 3

Patients 743 1,082

Primary Outcome Change in Best Corrected Visual Acuity (BCVA) from Change in Best Corrected Visual Acuity (BCVA) from Measures baseline at week 48 baseline at week 48

• Brolucizumab (RTH258) 3 mg/50 µL • Brolucizumab (RTH258) 6 mg/50 µL Arms/Intervention • Brolucizumab (RTH258) 6 mg/50 µL • Aflibercept 2 mg/50 µL • Aflibercept 2 mg/50 µL

Target Patients Subjects with exudative age-related macular degeneration Subjects with exudative age-related macular degeneration

Expected Completion Q1-2018 (actual) Q2-2018 (actual) • Oral presentations including both primary endpoint and key 2nd superior anatomic outcomes at AAO meetings in Nov- 2017 (1st year results) and Nov-2018 (2nd year results) • Year 1 Manuscript: Dugel P, et al. Ophthalmology 2019 Apr 12; HAWK and HARRIER: Phase 3, Multicenter, Publication Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. • Abstracts submissions on superior anatomic outcomes/Fluid/PostHoc results are planned for key retinal congresses (Angiogenesis/Mac Soc in Feb-2019; WRC in Mar-2019; ARVO in April-2019; ASRC July-2019; EURETINA Sept-2019; AAO Oct-2019 and APVRS Dec-2019

139 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation RTH258 - Anti-VEGF

Study NCT03386474 (CRTH258A2301E1) NCT03481634 KESTREL (CRTH258B2301) Indication Neovascular age-related macular degeneration (nAMD) Diabetic eye disease

Phase Phase 3 Phase 3

Patients 150 534

Primary Outcome Change from baseline in best-corrected visual acuity Number of treatment-emergent adverse events Measures (BCVA)

• Brolucizumab (RTH258) 3 mg/50 µL • Brolucizumab (RTH258) 6 mg/50 µL Arms/Intervention • Brolucizumab (RTH258) 6 mg/50 µL • Aflibercept 2 mg/50 µL • Aflibercept 2mg/50 uL

Patients with neovascular age-related macular degeneration Patients with visual impairment due to diabetic macular Target Patients who have completed the CRTH258A2301 study edema (DME) Expected Completion Q3-2018 (actual) H2-2021

Publication TBD TBD

140 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation RTH258 - Anti-VEGF

Study NCT03481660 KITE (CRTH258B2302) NCT04058067 KINGLET (CRTH258B2304) Indication Diabetic eye disease Diabetic macular edema

Phase Phase 3 Phase 3

Patients 356 268

Primary Outcome Change from baseline in best-corrected visual acuity Change in best-corrected visual acuity (BCVA) Measures (BCVA)

• Brolucizumab (RTH258) 6 mg/50 µL • Brolucizumab (RTH258) 6 mg/50 µL Arms/Intervention • Aflibercept 2 mg/50 µL • Aflibercept 2 mg/50 µL

Patients with visual impairment due to diabetic macular Patients with visual impairment due to diabetic macular Target Patients edema (DME) edema Expected Completion H2-2021 2022

Publication TBD TBD

141 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation RTH258 - Anti-VEGF

Study NCT03917472 KINGFISHER (CRTH258B2305) NCT03802630 RAPTOR (CRTH258C2301) Indication Diabetic macular edema Retinal vein occlusion

Phase Phase 3 Phase 3

Patients 500 500

Primary Outcome Change in best-corrected visual acuity (BCVA) from Change from baseline in best-corrected visual acuity Measures baseline up to week 52 (BCVA) at week 24

• Brolucizumab (RTH258) 6 mg/50 µL • Brolucizumab (RTH258) 6 mg/50 µL Arms/Intervention • Aflibercept 2 mg/50 µL • Aflibercept 2 mg/50 µL

Patients with visual impairment due to diabetic macular Adult patients with visual impairment due to macular edema Target Patients edema secondary to branch retinal vein occlusion Expected Completion H2-2021 2022

Publication TBD TBD

142 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation RTH258 - Anti-VEGF

Study NCT03810313 RAVEN (CRTH258C2302) NCT04047472 HOBBY (CRTH258A2307) Indication Retinal vein occlusion Macular degeneration

Phase Phase 3 Phase 3

Patients 750 494

Primary Outcome Change from baseline in best-corrected visual acuity Change from baseline in best-corrected visual acuity Measures (BCVA) at week 24 (BCVA) at week 48

• Brolucizumab (RTH258) 6 mg/50 µL • Brolucizumab (RTH258) 6 mg/50 µL Arms/Intervention • Aflibercept 2 mg/50 µL • Aflibercept 2 mg/50 µL

Adult patients with visual impairment due to macular edema Chinese patients with neovascular age-related macular Target Patients secondary to central retinal vein occlusion degeneration Expected Completion 2023 2023

Publication TBD TBD

143 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation UNR844 - Disulfide bonds modulator

Study NCT03809611 (CUNR844A2203) Indication Presbyopia

Phase Phase 2

Patients 124

Primary Outcome Change in binocular distance-corrected near visual acuity Measures (DNCVA) from baseline

• 1.5% solution UNR844-Cl Arms/Intervention • Placebo

Target Patients Patients with presbyopia

Expected Completion Q1-2020

Publication Planned in ASRCS in 2020

144 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Respiratory QAW039 – DP2 receptor antagonist

Study NCT02555683 LUSTER-1 (CQAW039A2307) NCT02563067 LUSTER-2 (CQAW039A2314)

Indication Asthma Asthma

Phase Phase 3 Phase 3

Patients 846 846

Primary Outcome Reduction in the rate of moderate-to-severe asthma Reduction in the rate of moderate-to-severe asthma Measures exacerbations exacerbations

• QAW039 Dose 1 • QAW039 Dose 1 Arms/Intervention • QAW039 Dose 2 • QAW039 Dose 2 • Placebo • Placebo

Target Patients Patients with uncontrolled severe asthma Patients with uncontrolled severe asthma

Expected Completion Q4-2019 (actual) Q3-2019 (actual)

Publication Planned in 2020 Planned in 2020

146 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation QAW039 – DP2 receptor antagonist

Study NCT03215758 ZEAL-1 (CQAW039A2316) NCT03226392 ZEAL-2 (CQAW039A2317) Indication Asthma Asthma

Phase Phase 3 Phase 3

Patients 650 650

Primary Outcome Pre-dose forced expiratory volume in 1 second (FEV1) Pre-dose forced expiratory volume in 1 second (FEV1) Measures

• QAW039 • QAW039 Arms/Intervention • Placebo • Placebo

Target Patients Patients with uncontrolled asthma Patients with uncontrolled asthma

Expected Completion Q3-2019 (actual) Q3-2019 (actual)

Publication Planned in 2020 Planned in 2020

147 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation QAW039 – DP2 receptor antagonist

Study NCT03052517 SPIRIT (CQAW039A2315) NCT03650400 (CQAW039B2201) Indication Asthma Asthma

Phase Phase 3 Phase 2

Patients 1,900 – 2,300 24

Long term safety: treatment emergent adverse event (AE), Primary Outcome SAE and AE leading to discontinuation from study (52 wks Pharmacokinetics, safety and tolerability Measures and 160 wks)

• QAW039 Dose 1 • Fevipiprant Cohort A; Fevipiprant Cohort B; Chewable Arms/Intervention • QAW039 Dose 2 tablet • Placebo

Target Patients Patients with moderate to severe asthma Children aged 6 to < 12 years with asthma

Expected Completion For Submission: Q4-2019 (actual); Final: 2022 Q3-2020 Publication TBD TBD

148 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation QBW251 - CFTR potentiator

Study NCT04072887 (CQBW251B2201) Indication Chronic obstructive pulmonary disease (COPD)

Phase Phase 2

Patients 900

Primary Outcome Trough FEV1 (Forced Expiratory Volume in 1 second) Measures change from baseline after 12 weeks of treatment • QBW251 450 mg • QBW251 300 mg • QBW251 150 mg Arms/Intervention • QBW251 75 mg • QBW251 25 mg • Placebo COPD patients on background triple inhaled therapy (LABA / Target Patients LAMA / ICS)

Expected Completion H2-2021

Publication TBD

149 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation QMF149 - Long-acting beta2 agonist and inhaled corticosteroid

Study NCT02892019 (CQMF149G2202) Indication Asthma

Phase Phase 2

Patients 80

Primary Outcome Trough FEV1 Measures

• Indacaterol acetate 75 μg od (via Concept1 inhaler) Arms/Intervention • Indacaterol acetate 150 μg od (via Concept1 inhaler)

Target Patients Children ≥ 6 to < 12 years of age with asthma

Expected Completion Q3-2019 (actual)

Publication Planned in H2-2020

150 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation QVM149 - Long-acting beta2 agonist, Long-acting muscarinic antagonist and inhaled corticosteroid

Study NCT02554786 PALLADIUM (CQVM149B2301) NCT02571777 IRIDIUM (CQVM149B2302) Indication Asthma Asthma

Phase Phase 3 Phase 3

Patients 2,216 3,092 Primary Outcome Trough FEV1 Trough FEV1 Measures

• QMF149 150/160 µg od • QVM149 150/50/160 µg od • QMF149 150/320 µg od • QVM149 150/50/80 µg od Arms/Intervention • MF 400 µg od • QMF149 150/160 µg od • MF 400 µg bid • QMF149 150/320 µg od • Salmeterol 50 µg /fluticasone 500 µg bid • Salmeterol 50 µg /fluticasone 500 µg bid

Adult and adolescent (≥12 years) patients with asthma Adult (≥18 years) patients with asthma inadequately Target Patients inadequately controlled on medium/high-dose ICS or low- controlled on medium/high-dose of LABA/ICS (GINA step ≥4) dose LABA/ICS (GINA step ≥ 3) Expected Completion Q3-2019 (actual) Q3-2019 (actual) • Planned in H1-2020 • Planned in H1-2020 Publication • Abstract: van Zyl-Smit et al, presented at BTS Dec-2019 • Abstract ATS Q2-2020

151 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation QVM149 - Long-acting beta2 agonist, Long-acting muscarinic antagonist and inhaled corticosteroid

Study NCT03100500 (CQVM149B1305) NCT03100825 (CQVM149B1304) Indication Asthma Asthma

Phase Phase 3 Phase 3

Patients 51 94 Long-term safety/tolerability: Incidence and severity of Long-term safety/tolerability: Incidence and severity of Primary Outcome treatment emergent adverse events during the 52 weeks treatment emergent adverse events during the 52 weeks Measures study study

Arms/Intervention • Single arm: QMF149 150/320 μg od • Single Arm: QVM149 150/50/160 μg od

Target Patients Japanese patients with asthma inadequately controlled Japanese patients with asthma inadequately controlled

Expected Completion Q1-2019 (actual) Q2-2019 (actual) • Planned in H1-2020 • Planned in H1-2020 Publication • Abstract for ATS in Q2-2020 • Abstract for ATS in Q2-2020

152 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation QVM149 - Long-acting beta2 agonist, Long-acting muscarinic antagonist and inhaled corticosteroid

Study NCT02892344 QUARTZ (CQVM149B2303) NCT03158311 ARGON (CQVM149B2306) Indication Asthma Asthma

Phase Phase 3 Phase 3

Patients 802 1,251 Primary Outcome Non-inferiority of Asthma Quality of Life Questionnaire Trough FEV1 Measures (AQLQ)

• QVM149 150/50/80 μg od • QMF149 150/80 µg od Arms/Intervention • QVM149 150/50/160 μg od • MF 200 µg od • Salmeterol/fluticasone 50/500 μg bid + tiotropium 5 μg od

Adult and adolescent (≥12 years) patients with mild asthma Target Patients inadequately controlled on low-dose ICS or low-dose Patients with uncontrolled asthma LABA/ICS (Gina step 2-3) Expected Completion Q1-2019 (actual) Q3-2019 (actual) • O. Kornmann et al. Respiratory Medicine 161 (2020) • Planned in H1-2020 Publication • Abstract: D’Andrea et al, presented at ERS Sep-2019 • Abstract ATS Q2-2020

153 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Xolair ® – anti-IgE antibody

Study NCT03369704 (CIGE025F1301)

Indication Seasonal allergic rhinitis: Severe Japanese Cedar Pollinosis

Phase Phase 3

Patients 337

Primary Outcome Measures Mean nasal symptom score, consists of severity of sneezing, rhinorrhea and nasal congestion.

In addition to standard of care: Arms/Intervention • Omalizumab per approved allergic asthma dosing table for IgE/body weight combinations • Placebo Patients with severe Japanese cedar pollinosis, whose symptoms were inadequately controlled with current recommended Target Patients therapies Expected Completion Q1-2019 (actual) • Late breaking abstract was published at AAAAI (American Association of Allergy, Asthma and Immunology) annual meeting, Feb 2019 • Poster published at EAACI (the European Academy of Allergy and Clinical Immunology), Jun 2019 Publication • Oral presentations were made at JRS (Japanese Rhinologic Society), Oct 2019, and Asian Pacific Society of Respirology congress, Nov 2019 • Planned oral/poster presentation at Japan society of Immunology & Allergology in Otolaryngology, Feb 2020 • Planned manuscript to be submitted to JACI in Practice, Q1 2020

154 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Sandoz Biopharmaceuticals Hyrimoz® - Biosimilar adalimumab

Study NCT02744755 ADMYRA (GP17-302) Indication Immunology Phase Phase 3 Patients 353 Change in DAS28-CRP score from baseline to week 12 in Primary Outcome patients treated with GP2017 and patients treated with Measures Humira®

• GP2017 Arms/Intervention • US licensed Humira® adalimumab

Target Patients Patients with moderate to severe active rheumatoid arthritis

Expected Completion 2018 (actual)

• Wiland, P. et al., presented at EULAR 2019 Publication • Wiland, P. et al., BioDrugs, Q4 2019

156 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation GP2411 - Biosimilar denosumab

Study NCT03974100 (CGP24112301) Indication Osteoporosis Phase Phase 3 Patients 522

Primary Outcome Percent change from baseline (%CfB) in lumbar spine Bone Measures Mineral Density

• GP2411 60 mg /mL subcutaneous injection every 6 months Arms/Intervention • Prolia® 60 mg /mL subcutaneous injection every 6 months

Target Patients Postmenopausal women with osteoporosis

Expected Completion 2022

Publication Study data publications expected for 2024 and beyond

157 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Global Health KAF156 – Plasmodium Falciparum Inhibitor – PfCARL mediated

Study NCT03167242 (CKAF156A2202) Indication Malaria

Phase Phase 2

Patients 512

Primary Outcome PCR-corrected adequate clinical and parasitological Measures response (ACPR)

• KAF156 and LUM-SDF (different combinations) Arms/Intervention • Coartem

Adults and children with uncomplicated Plasmodium Target Patients Falciparum Malaria

Expected Completion H1-2021

Publication TBD

159 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation KAE609 – Plasmodium Falciparum Inhibitor – spiroindolone against PfATP4

Study NCT03334747 (CKAE609A2202) Indication Malaria

Phase Phase 2

Patients 210 CTCAE grades increase from baseline in alanine Primary Outcome aminotransferase (ALT) or aspartate aminotransferase Measures (AST)

• KAE609 Arms/Intervention • Coartem

Target Patients Adults with uncomplicated Plasmodium Falciparum malaria

Expected Completion Q4-2020

Publication TBD

160 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation